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ABSTRACT 
Retroviruses include two subfamilies, orthoretrovirinae and 
spumaretrovirinae.  The human immunodeficiency virus 1 (HIV-1) belongs 
to the orthoretrovirinae subfamily and is the causative agent of acquired 
immunodeficiency syndrome (AIDS). HIV-1 infects 36.9 million people and 
2.6 million children throughout the world. During primary infection HIV 
converts its RNA genome into DNA, which integrates into the host genome. 
The cellular environment present at the site of the integration may 
influence viral transcriptional activity. The sequestration of host 
transcription factors, the presence of repressor of transcription and 
nucleosomes and epigenetic modifications on the HIV promoter, or 
transcriptional modification of Tat are all conditions that influence the 
formation of long term viral reservoirs. The use of antiretroviral drugs has 
been proposed as a functional cure to control the viral load but lacks the 
ability to obtain viral sterilization since antiretroviral drugs can not remove 
the virus from latently infected cells and anatomical sanctuaries such as 
brain and the gut associated lymphoid tissue. In recent years gene editing 
strategies have been largely employed for the treatment of HIV-1. In this 
present study, we aimed to discover an innovative CRISPR technology 
specific against the HIV viral genome that can target latently infected cells 
and be delivered in all tissues. Initially, we performed in vitro analysis, 
where TZMB-1 cells containing the luciferase gene under the control of 
LTR were transfected with pCMV-Tat and three plasmids harboring Cas9 
under the control of different regions of LTR promoter to evaluate by 
western blot analysis the minimal LTR promoter region able to activate 
Cas9 in presence of Tat. TZMB-1 cells were transduced with the 
lentiviruses, harboring Cas9 or gRNAs specific for the promoter region, and 
infected with HIV-1 to test, by PCR and luciferase assay, the presence of 
gene editing. Then PCR and flow cytometric analyses were performed on 
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2D10 cells, HIV-1 latently infected cells, to test the ability of Tat-induced 
Cas9 to excise viral DNA.  Subsequently, was evaluated the ability of 
Cas9, in presence of gRNAs, to protect Jurkat cells from viral reinfection by 
eliminating the virus during the early stages of infection. The second part of 
our study was performed to test Cas9 and gRNAs specific for HIV-1 LTR 
and Gag regions in vivo using adeno-associated virus (AAV) as the 
delivery system.  Tissues of HIV-1 transgenic mice and rats and 
humanized mice were provided by collaborators for evaluation by analyzing 
DNA and RNA for the presence of viral editing. Results from in vitro 
experiments showed the ability of Tat to activate the minimal promoter 
LTR, inducing gene editing in TZMb-I and 2D10 cells. The presence of 
Cas9 in Jurkat cells induces a reduction of viral RNA of 96% at five days 
from infection. Studies in vivo showed the presence of viral excision in 
blood, heart, liver, lung, kidney, spleen and brain in transgenic mice and a 
reduction of viral RNA in the blood of transgenic rats. Excision of HIV-1 
was reported in the spleen, gut associated lymphoid tissue, liver, kidney, 
lung and brain of humanized mice with complete viral sterilization in 29% of 
the infected animals that were subjected to antiretroviral treatment. The 
absence of off-target effects was confirmed by deep sequencing analysis. 
Together, these data show the ability to create a Cas9-inducible system 
generating negative feedback against the virus while avoiding persistent 
Cas9 expression in the cells. The use of AAV vectors in vivo showed high 
delivery efficiency in the different tissues, obtaining viral sterilization for the 
first-time. Further experiments on humanized mice and SIV infected 
monkey models will show this approach combined with ART therapy may 
have important application for HIV-1 sterilization in clinical trials.    
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SOMMARIO 
Retroviruses includono due sottofamiglie, gli Orthoretrovirinae e 
Spumaretrovirinae. Il virus dell’immunodeficienza umana (HIV) appartiene 
alla sottofamiglia degli Orthoretrovirinae ed e’ considerato l’agente 
causativo della sindrome dell’immunodeficienza acquisita (AIDS). Ad oggi 
36,9 milioni di individui, di cui 2,6 milioni di bambini nel mondo convivono 
con l’infezione da HIV-1. Durante l’infezione primaria, dopo la conversione 
di HIV-1 RNA in DNA, il virus integra il suo genoma nel DNA dell’ospite. L’ 
ambiente cellulare presente a livello del sito di integrazione influenza la 
replicazione e la trascrizione virale. Il sequestro di fattori di trascrizione 
cellulari, la presenza di repressori di trascrizione e nucleosomi e 
modificazioni genetiche a livello del promotore virale o modificazioni 
trascrizionali di Tat sono tutte condizioni che incidono sulla formazione di 
reservoir virali a lungo termine.  L’uso di farmaci antiretrovirali e’ stato 
proposto come cura funzionale in grado di mantenere la carica virale sotto 
il limite di detezione, ma la mancanza di azione a livello delle cellule 
reservoir e il mancato raggiungimento di organi come il sistema nervoso 
centrale (SNC) o il tessuto linfoide associate all’intestino rappresenta un 
grosso limite di questi farmaci.  In questi ultimi anni l’uso di gene editing 
per il trattamento di HIV-1 e’ stato impiegato da differenti laboratori. Il 
presente studio ha come scopo la realizzazione di un nuovo costrutto 
usando un efficace sistema di delivery per targettare le cellule reservoir e 
raggiungere i diversi tipi di tessuti. Inizialmente e’ stato condotto uno studio 
in vitro, cellule TZMB-1 contenenti il gene per la luciferasi sotto il controllo 
di LTR sono state transfettate con pCMV-Tat e tre plasmidi contenenti 
Cas9 sotto il controllo di diverse regioni del promotore per individuare 
attraverso western blot la minima regione di LTR in grado di attivare la 
trascrizione di Cas9 in presenza di Tat. TZMB-1 cellule sono state 
trasdotte con lentivirus contenenti Cas9 e gRNAs specifici per il promotore 
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LTR e infettate con HIV-1 per valutare la presenza di LTR editing mediante 
saggi di PCR e luciferasi. Successivamente analisi di PCR e cito-
fluorimetriche sono state condotte per valutare l’abilita’ del costrutto Cas9, 
Tat-indotto, di escidere il virus in cellule 2D10, modello cellulare di 
infezione latente. Infine e’ stata testata la capacita’ di Cas9 in presenza dei 
gRNAs di proteggere le cellule Jurkat da reinfezione virale eliminando il 
virus nello stadio iniziale dell’infezione. La seconda parte del nostro studio 
e’ stata condotta per testare Cas9 e gRNAs specifici per il promotore LTR 
e la regione Gag, in vivo usando adeno-associati virus (AAV) come 
sistema di delivery. Tessuti di topi e ratti HIV-1 transgenici e di topi 
umanizzati, sono stati forniti da collaboratori per valutare attraverso analisi 
del DNA e RNA la presenza di editing virale. Risultati ottenuti dagli 
esperimenti in vitro hanno dimostrato l’abilita’ di Tat di attivare la minima 
regione del promotore LTR, inducendo gene editing in cellule TZMb-I e 
2D10. La presenza di Cas9 nelle cellule Jurkat induce una riduzione dei 
trascritti virali del 96% a cinque giorni dall’infezione. Studi in vivo hanno 
dimostrato la presenza di eliminazione virale in diversi tessuti come 
sangue, fegato, polmoni, rene, milza e cervello in topi transgenici ed una 
riduzione del RNA virale nel sangue dei ratti transgenici. Editing di HIV-1 e’ 
stato osservato nei tessuti di milza, tessuto linfoide associato all’intestino, 
fegato, rene, polmone e cervello dei topi umanizzati con completa 
sterilizzazione virale nel 29% degli animali precedentemente trattati con 
terapia antiretrovirale. Questi risultati, hanno dimostrato la capacita’ di 
creare un nuovo sistema di gene editing attivato dalla presenza del virus 
nella cellula creando un feedback negativo contro lo stesso virus ed 
evitando la persistente espressione di Cas9 nelle cellule. L’uso di AAV in 
vivo, ha dimostrato alta efficienza di delivery nei diversi tessuti, ottenendo 
completa sterilizzazione virale. Questi dati, se confermati da ulteriori 
esperimenti sui topi umanizzati e modelli di scimmia infettati con SIV, 
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combinati con la terapia antiretrovirale possono avere importanti 
implicazioni per la cura di HIV-1 in trial clinici.  
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1. Introduction 
1.1 Human Immunodeficiency Virus 
Retroviruses are spherical viruses of 80-120 nm in diameter [1] sharing 
similar structure, genomic organization and replicative strategy. The 
retroviridae family is composed of two virus subfamilies, Orthoretrovirinae 
and Spumaretrovirinae. The Spumaretrovirinae subfamily only includes 
Spumaviruses, and the Orthoretrovirinae subfamily includes six viral 
genera, Alpharetrovirus, Betaretrovirus, Deltaretrovirus, Epsilonretrovirus, 
Gammaretrovirus and Lentivirus. Lentiviruses are characterized by 
persistent infection in humans and animals. Lentiviruses include human 
immunodeficiency viruses 1 and 2, HIV-1 and HIV-2. 
 
Figure 1: Illustration of the Retroviridae family (Reproduced under open access) [2]. 
1.1.1 Epidemiology 
The HIV-1 epidemic initiated with zoonotic transmission from primates of 
Africa infected with Simian Immunodeficiency Viruses (SIV) throughout the 
1900s. There are two recognized types of HIV, HIV type 1 and HIV type 2, 
which have different original transmission origins. Chimpanzees and 
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mangabey monkey are hypothesized to have transmitted HIV-1 and HIV-2 
to humans, respectively [3]. HIV-2 is restricted to Western Africa and 
causes a disease like HIV-1, but is less transmissible and has decreased 
virulence [4]. HIV-1 originated from four different transmission to human, 
three from chimpanzee and one from gorillas. The groups N and P derive 
from chimpanzee and gorillas respectively and are diffused throughout 
Western Africa. The main group (M) derives from chimpanzees and is the 
source of the worldwide HIV pandemic. The M group includes nine viral 
subtypes: A-D, F-H, J and K. The most widespread subtypes are C, which 
is responsible of 48 % of infection in Africa and India [5], and B, which is 
diffused throughout Western Europe, America and Australia. Different HIV 
subtypes have different rates of transmission and disease progression. 
 In 1980 a new disease, acquired immunodeficiency syndrome (AIDS), was 
recognized by studying cases of young homosexual men in the United 
States affected with Pneumocystis carinii pneumonia (PCP) and Kaposi's 
sarcoma (KS) [6]. After two years, HIV-1 was recognized as the causative 
agent of AIDS. Since then 76.1 (65.2 - 41.5) million people in the world 
became infected with HIV-1 and today roughly 36.5 (30.8 – 42.9) million 
people live with HIV infection, including 2.1 million children under the age 
of 15 [7]. HIV-1 infection in 2010 was the main cause of morbidity in the 
world for people aged 30-44 years [8] with the highest incidence in sub-
Saharian Africa. HIV prevalence is higher in people with risk behaviors 
such as homosexual men and drug users [9]. One million (830.000 -
1.200.000) AIDS related deaths were reported in 2016, while 35.0 million 
(28.9 – 41.5) AIDS related deaths have been reported since the start of the 
HIV-1 epidemic. The number of AIDS related deaths decreased by 48 % 
after peaking in 2005 when there were 1.9 million AIDS related deaths. 
Tuberculosis is the main source of death among HIV-1 infected patients 
(350.000 deaths in 2015) with 1.2 million of people living with HIV also 
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having tuberculosis. The global prevalence of HIV-1 after the introduction 
of antiretroviral therapy (ART) decreased by 11% among adult and by 47% 
among children from 2010 to 2016. [7]. In 2014, the Joint United Nations 
Program on HIV and AIDS (UNAIDS) set up the program “90-90-90 
targets”. The goal of this program is to reach these three important results 
by 2020 [10]: 
1) Diagnose HIV-1 infection in 90% of people living with HIV-1  
2) Start ART treatment in 90% of diagnosed people 
3) Reach fully suppressed viral load in 90% of ART patients 
So far, it is hypothesized that 70% of all HIV-1 positive people are 
diagnosed, with 53% of patients undergoing ART and around 44% 
demonstrating viral suppression.  Large disparities exist for these statistics 
between different countries [7]. 
 
 People living with 
HIV (all ages) - by 
region 
AIDS-related deaths 
(all ages) - by 
region 
REGION   
Asia and the Pacific 5.1 million 170000 
Caribbean 311000 9400 
East and Southern Africa 19.4 420000 
Eastern Europe and Central 
Asia 
1.6 40000 
Latin America 1.8 36000 
Middle East and North Africa 231000 11000 
West and Central Africa 6.1 310000 
Western & Central Europe 
and North America 
2.1 18000 
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Table 1: 2016 Regional HIV and AIDS Statistics. Data from UNAIDS showing the number 
of patients with HIV and number of AIDS-related deaths in different regions of the world in 
2016. (Table created using the ufficial data from UNAIDS, special analysis, 2017) [7]. 
 
Figure 2: 2016 Global HIV patients testing and treatment. Percentage of HIV-1-positive 
patients aware of their status, patients undergoing ART therapy, and patients with viral 
suppression in the world during 2016. (Figure created using the ufficial data from UNAIDS, 
special analysis, 2017) [7] 
1.1.2 HIV Transmission and Pathogenesis 
HIV-1 sexual transmission risk increases in the initial months of HIV-1 
infection, which is characterized by high viral plasma load, and is also 
influenced by other factors including seminal and cervical viral load [11]. 
Genital ulcers, herpes simplex type 2 infection, bacterial vaginosis, 
pregnancy, anal intercourse and injection drug use are factors increasing 
HIV-1 transmission risk [12]. The HIV-1 mother to child transmission risk is 
about 15-25% during pregnancy, increasing to 35-40% during 
breastfeeding [13]. Initiation of ART therapy reduces the probability of 
transmission to the infant by reducing maternal viral load. CD4+ T cells in 
mucosal tissues are the first targets of HIV-1 during the early stages of 
infection, followed by viral spread thoughout the lymphoid system, a stage 
called the eclipse phase. HIV-1 RNA levels are detectable after several 
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days of infection and reach 106-107 copies/ml after a month. This stage of 
primary or acute infection can be asymptomatic or characterized by fever, 
lymphadenopathy, rash, malaise or myalgias and more rarely by 
meningitis. Rash is present in 40-80% of cases and is typically 
maculopapular and involves the trunk [14]. After progressive depletion of 
infected CD4+ T cells, the immune system establishes partial control of the 
virus. However, the antibody response is unsuccessful against HIV-1 
variants, resulting in viral escape. After 4-6 months, the plasma viral load 
decreases by about 100-fold, reaching a viral set point ranging from few 
copies of virus/ml to 106 copies/ml due the action of CD8+ cytotoxic T 
lymphocytes (CTLs). The viral plasma load directly influences disease 
outcome and progression towards AIDS [15]. This phase is generally 
asymptomatic and can exist for up to 15 years, resulting in the constant 
destruction of CD4+ cells and the presence of chronic inflammation 
(chronic phase) and inactivation of CTLs. In the final stage of infection, 
AIDS phase, the level of CD4+ T cells per μl of blood reaches < 100 
cells/μl [9]. This phase is characterized by weight loss, fever, cough, 
increased risk of myocardial infarctions, liver disease in presence of 
coinfection of hepatitis B and C, HIV-1-related tuberculosis mortality and 
the development of opportunistic illnesses such as Candida in the 
esophagus, trachea, bronchi and lungs, invasive cervical cancer, 
cytomegalovirus disease, HIV-related encephalopathy, Karposi’s sarcoma, 
Burkitt lymphoma, immunoblastic or primary brain lymphoma, 
toxoplasmosis of the brain, Salmonella septicemia and Herpes Simplex 
Virus infection involving skin or lungs problems [16], [17], [18], [19]. 
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Figure 3: HIV-1 Infection Phases. Acute phase (6-12 weeks) is charactherized by flu-like 
sympotoms, a peak in viral load and acute loss of CD4+T cells. Chronic phase can last 
between 7 to 10 years and is characterized by clinical latency. Sympoms appear during the 
AIDS phase where a high viral load and the decline of the CD4 T cells results in the 
development of opportunistic diseases and death. (Figure reproduced with permission from 
An P. et al., 2010 and Elsevier) [20] 
 
1.1.3 HIV-1 Diagnosis 
After HIV-1 exposure, HIV antibody presence may be absent for weeks or 
months during the so-called window period [21]. Nucleic acid tests are 
recommended in presence of high risk of acute infection. [9]. HIV RNA 
assays are characterized by 100% sensitivity and 97.4% specificity [22]. 
The US Centers for Disease Control and Prevention suggests an antigen 
antibody assay for the rapid detection of the virus during acute infection. 
Rapid HIV testing using blood from a finger stick or collection of oral fluid 
give results within 30 minutes.  
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1.1.4 HIV Genome 
The genome of HIV-1 is characterized by two linked copies of single 
stranded RNA, less than 10 kb in length, containing coding and non-coding 
regions involved in the production of regulatory and accessory proteins and 
in the regulation of viral expression respectively. The long terminal repeats 
(LTRs) at the ends of the provirus are characterized by two untranslated 
regions (U3 and U5) and a repeat element (R). LTRs are constituted by an 
enhancer/promoter sequence, ATT repeats involved in provirus integration, 
a primer binding site (PBS), a packaging signal ψ and a polyadenylation 
signal (polyA). The ψ-site is between the 5’LTR and the gag initiation 
codon and contains four stem loops (SL1-SL4) important for encapsidation. 
The enhancer sequence binds the transcription factor kappa-light-chain-
enhancer of activated B cells (NF-KB) and Nuclear factor of activated T-
cells (NFAT) [23]. The  HIV-1 promoter includes 3 important elements, 
stimulatory protein 1 (SP1) binding sites [24], a TATA element (TATAAA) 
[25], and an active initiator sequence [26], that allows the interaction 
between transcription factor TFIID and TATA binding protein associated 
factor (TAF) with the TATA element [27]. 
HIV-1 contains three main structural genes, gag which codes for matrix, 
capsid, nucleocapsid and p6 proteins, pol encoding for the protease, 
reverse transcriptase (RT) and integrase and env encoding the envelope 
proteins gp41 and gp120. Other proteins include Vif, Vpu/Vpx, Vpr and the 
negative regulatory factor (Nef) [28] 
 
12 
 
 
Figure 4: HIV Genome Map and Structural Biology. Representation of the HIV-1 (panel 
A) and HIV-2 (panel B) full length genomes. Structural represenations and a schematic of 
the HIV-1 viral particle show localization and protein-protein intereactions of each viral 
protein.  (Figure reproduced with permission from Li G. et al., 2016 and the American 
Society of Microbiology) [28] 
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1.1.5 HIV Structural Biology 
The HIV envelope proteins gp41 and gp120 possess spikes decorated with 
carbohydrates and bind host receptors allowing viral penetration into host 
cells. The cleavage of the structural Gag polyprotein during the viral 
maturation results in the production of proteins within the matrix (MA), of 
the capsid (CA), of the nucleocapsid (NC) and p1, p2 and p6 proteins [28].  
The matrix protein (p17) is characterized by five α-helices, a 310 helix and 
a three-stranded mixed β-sheet. The carboxy-terminal α-helix connects the 
MA domain with the adjacent CA domain. MA proteins assemble into 
trimers that interact with the acid inner membrane of the virus, creating a 
coat of the viral membrane. An important function of these proteins is the 
transport of P55GAG protein to the cellular membrane, allowing the 
assembly of gp120 and gp41 into the viral particles [29]. 
The capsid protein forms stable hexamers which form a cone-shaped coat 
around the viral RNA. The HIV-1 capsid binds to the cellular proline 
isomerase cyclophilin A in the viral particle.  
The NC protein contains two zinc-finger-like domains and interacts with the 
viral genome. This protein is involved in the recognition and packaging of 
reverse transcriptase, the primer tRNALys3 and the viral genome, interacting 
with almost 120 nucleotides of the unspliced RNA ψ-site [30], [31]. After a 
protease processes the Gag precursor, NC creates a ribonucleoprotein 
complex and allows the tRNALys3 primer to anneal to the viral RNA initiating 
reverse transcription. Likewise, NC facilitates the elongation of viral DNA 
and is involved in viral particle formation. Mutations in conserved regions of 
the NC gene can alter RNA packaging specificity [32], [33]. 
HIV-1 protease is a homodimer containing an active site at the interface of 
the two subunits, formed by a catalytic triad (Asp25- Thr26-Gly27) 
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responsible for cleavage. Mutations of this protein can alter cleavage 
efficiency resulting in the production of dysfunctional cores [34]. 
HIV-1 reverse transcriptase is the protein involved in the retro-transcription 
of viral RNA into DNA. This protein is introduced in the viral particles as 
part of Gag Pol precursor and later processed as a mature p66-p51 RT 
heterodimer containing polymerase and an Rnase H domain. The first 
domain can copy either DNA or RNA templates, while the RNase H domain 
cleaves RNA of RNA/DNA duplexes. For the synthesis of viral DNA, RT 
requires a host tRNAlys3 primer containing an 18-nucleotide sequence at the 
3’ end, complementary to the primer binding sequence at 5’ end of the viral 
genome. RT synthesizes the negative RNA strand using the positive strand 
as a template, creating a RNA/DNA hybrid. The minus strand DNA 
hybridizes with the 3’end of one of the two viral RNAs present in the viral 
particle, first jump, allowing the rest of synthesis of the minus strand DNA 
followed by the degradation of the RNA strand. The polypurine tract at the 
3’ extremity of the RNA is not damaged by the RNase H activity and is 
used like a primer for positive DNA strand synthesis. After initial synthesis 
RT copies the first 18 nucleotides of the tRNA and RNase H remove one 
nucleotide from the tRNA/DNA junction, leaving a ribo-A on the 3’ end of 
the viral negative strand DNA. The elimination of the tRNA allows the 
exposure of a single strand portion of the positive DNA strand, which 
contains a complementary sequence to the PBS site. After the synthesis of 
this region on the negative DNA strand, the 5’end is transferred to the 
positive strand (second jump) allowing the extension of both strands. The 
produced DNA has the same sequences at both ends and is longer than 
the initial RNA. The viral DNA, after integration, serves as stamp for viral 
replication using host enzyme DNA-dependent RNA polymerase [35]. 
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Figure 5: Reverse Transcription of HIV-1 RNA. Model of HIV-1 reverse transcription into 
positive and negative strands of viral DNA. (Figure reproduced by permission from 
Sarafinos SG. et al., 2009 and Elsevier) [35] 
HIV-1 integrase (IN) is a viral enzyme consisting of 3 functional domains, a 
N-terminal zinc binding domain, a C-terminal DNA-binding domain and a 
central catalytic domain. IN is part of the pre-integration complex (PIC) and 
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recognizes the 3’ LTRs of the viral DNA complex, cutting two or three 
nucleotides at the 3’ end. The enzyme ligates the 3′-hydroxyl group of the 
end of the 3’ viral DNA to a pair of phosphodiester bonds in the host DNA.  
 
Cellular enzymes remove the two unpaired nucleotides at the 5′ end of the 
viral DNA and the DNA polymerase extends the unligated 3’ end of the 
human DNA, resulting in the incorporation of proviral DNA into the cellular 
genome. Analysis of the integration sites used by HIV-1 in the cellular 
genome revealed a low degree of specificity [36]. 
 
Nef is a 27 kDa accessory protein abundantly produced during the early 
phase of viral expression (37).  A majority of Nef proteins are incorporated 
into the virions and are cleaved by the viral protease resulting in 
association with the viral core (38). Nef is involved in the downregulation of 
the CD4 receptor by linking the tail of CD4 to the clathrin adapter protein 
complex 2 (AP-2), resulting in the internalization and degradation of the 
receptor, preventing reinfection by new viral particles [39]. Nef is also 
involved in the downregulation of major histocompatibility complex class I 
(MHC-I), mature MHC-II, CD28, CCR5 and CXCR4 receptors on the 
surface of infected CD4+ T-lymphocytes [40], [41]. The regulation of MHC-I 
involves clathrin adapter protein complex 1 (AP-1) or sarcoma (SRC) 
family kinase-ZAP70/Syk-PI3K cascade recruited by phosphofurin acidic 
cluster sorting protein 1 (PACS2). The decrease of MHC-I expression from 
CD4+ cells and the consequent upregulation of Fas ligand (FasL) 
molecules results in the apoptosis of infected CD8+ T cells. Nef down-
regulates host antiviral proteins serine incorporator 3 and 5 (SERINC3 and 
SERINC5), which decreases the incorporation of env proteins into the 
virions, allowing the spread of infection. NF also alters several functions of 
dendritic cells, monocytes/macrophages and NK cells [42], [43]. 
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Rev is a 116 amino acids protein composed of two domains, an amino-
terminal domain, harboring the nuclear localization signal (NLS), and a 
RNA-binding domain, carrying the nuclear export signal (NES) [44]. The 
major role of Rev is the regulation of HIV-1 protein expression and the 
export rate of mRNA. HIV-1 gene expression can be classified into early 
stage (Rev-independent) for the expression of the regulatory proteins Tat, 
Rev and Nef and late stage (Rev-dependent) for the expression of the 
remaining proteins [45], [46]. HIV-1 mRNA is subjected to three different 
splicings, the ~9 kb unspliced mRNA (genomic and gag and pol mRNA), 
the ~4 kb single spliced (encoding a truncated 72 amino acids form of Tat, 
Env, Vpu, Vif and Vpr) and the ~1.8 kb doubly spliced (early transcripts that 
encoding Tat, Rev and Nef). Doubly spliced mRNAs are small and 
immediately exported to the cytoplasm and translated into proteins. The 
other transcripts require the action of Rev for cytoplasmic transport as Rev 
recognizes and interacts with the Rev responsive element (RRE), present 
in unspliced and single spliced transcripts. The Rev NLS sequence binds 
directly to KPNB1/Importin beta-1 complex, and KPNB1 binds Ran-GDP 
form, allowing the transport of Rev into the nucleus, where Ran GDP is 
converted in Ran-GTP and Rev dissociated from KPNB1 and associates 
with the region RRE of the immature transcripts. This binding exposes the 
NES site of Rev allowing the binding of this protein with exportin 
XPO1/CRM1 complex and Ran-GTP and the nuclear export of the 
complex. Rev can regulate expression of viral proteins like Tat, keeping a 
correct equilibrium between early and late viral gene expression.  Without 
Rev the transcripts are not translated into viral proteins [47].  
Viral protein U (Vpu) is a 16 kDa protein translated from vpu-env bicistronic 
mRNA. The N terminal domain is characterized by a transmembrane (TM) 
domain involved in the regulation of viral release. The phosphorylation of 
serine residues within the C-terminal cytoplasmic domain is critical for CD4 
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degradation in the endoplasmic reticulum [48]. Vpu induces ubiquitination 
and the protoseomal degradation of BST2, an interferon (IFN)-inducible 
cell surface protein that interferes with the release of the viral particles in 
absence of Vpu [49]. 
Vif is a 23 kDa protein essential for viral replication. Vif inhibits the antiviral 
activity of the cellular apolipoproteins B mRNA editing enzyme catalytic 
subunits 3F and 3G (APOBEC3F and APOBEC3G) via proteosomal 
degradation and inhibition of the mRNA translation respectively, preventing 
the incorporation of these enzymes into new virions.  In the absence of Vif, 
these proteins cause hypermutation of the viral genome influencing the 
stability of the viral nucleoprotein core and contributing to the G2 cell cycle 
arrest in HIV infected cells [50].   
Vpr (viral protein r) is a 14 kDa protein involved in the transport of the PIC 
complex to the nucleus. It can associate with DNA damage-binding protein 
1 (DDB1) as part of E3 ubiquitin ligase complex targeting specific host 
proteins for proteosomal degradation. The association of Vpr with the 
cellular CUL4A-DDB1 E3 ligase complex may result in cell cycle arrest or 
apoptosis of the infected cells [51]. Vpr carried into the virions can arrest 
cell cycle in G2 phase within hours of infection, increasing viral expression 
and can induce apoptosis by interacting with mitochondrial permeability 
transition pore complex (PTPC). This interaction results in a lost of the 
mitochondrial transmembrane potential and in a mitochondrial release of 
apoptogenic proteins such as cytochrome C or apoptosis inducing factors. 
Vpr can regulate the tumor suppressor p53-induced transcription [52].  
 
1.1.6 Regulatory Tat protein 
Tat is a 14-kDa regulatory protein important for the expression of HIV-1 
genes. In presence of Tat, the activity of RNA polymerase is stabilized 
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allowing increased elongation of the viral transcripts [53]. The binding of 
Tat to a transactivation response region (TAR) at 3’ region of the initiation 
site of transcription of the mRNA originates a stem loop complex, nuclease 
resistant, and a conformation change of the RNA structure [54]. Mutations 
present in the TAR RNA loop, but not specifically to the region recognized 
by Tat, interfere with transactivation [55], which suggests the presence of a 
cellular cofactor involved in the mechanism of regulation of gene 
expression [56]. Herrmann et al. described the presence of a protein 
kinase complex binding Tat, Tat-associated kinase (TAK) [57], [58]. Tat 
and TAR RNA interact with the two components, CDK9 and cyclin CycT1, 
of the positive transcription elongation factor pTEFb, a cofactor of HIV-1 
elongation. The interaction between Tat and CycT1 yield conformational 
changes, resulting in CDK9 activation [59]. P-TEFb activated by Tat 
regulates elongation via phosphorylation of different elongation factors. In 
absence of Tat, the negative elongation factor (NELF) blocks the 
transcription via interaction of its subunit E with TAR region [60]. After 
activation by Tat, p-TEFb phosphorylates NELF-E, which dissociates from 
TAR and this release stops transcription elongation complexes. In absence 
of Tat, inactive p-TEFb molecules are sequestered by a 7SK RNP complex 
formed by 7SK RNA and RNA-binding proteins. During the elongation 
process the Tat/PTEFb complex phosphorylase RNAPII CTD and a subunit 
of the DRB sensitivity inducing factor (DSIF), [47] increasing elongation 
efficiency. Interaction of human transcription factors FF4, ENL, AF9, ELL2 
with the Tat P-TEFb complex increases the elongation process [61]. Tat 
mediates the nuclear translocation of NF-kappa-B via oxidative stress-
induced cell signaling pathway like the PI3K/Akt signaling pathway to 
increase the transcriptional elongation [62]. In absence of Tat, RNA Pol II 
generates non-processive transcripts that terminate at approximately 60 
bases from the initiation site. Circulating Tat acts like a chemokine or 
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growth factor-like molecule and interferes with many cellular pathways. The 
recruitment of histone acetyltransferases (HATs) Cyclic-AMP response 
element binding protein B (CREBBP), E1A binding protein p300(EP300) 
and acetyl-CoA acetyltransferase (PCAF) by Tat to the chromatin 
increases proviral transcription especially in latently infected cells 
transactivating LTR promoter [63]. Tat can be endocytosed by surrounding 
uninfected cells, like neurons, leading to apoptosis and the progression of 
HIV-Associated Neurocognitive Disorders (HAND) [64]. 
        
Figure 6: Interaction of Tat with NF-KB and P-TEFb. NF-kB promotes the initiation of viral 
transcription, then the Tat/P-TEFb complex interacts with the TAR region to create the 
elongation factor complex and the phosphorylation of RNAP and efficient elongation.  
(Figure reproduced with permission from Karn J. et al., 2012 and Cold Spring Harbor 
Perspective in Medicine) [47]. 
1.1.7 HIV-1 replication cycle 
The HIV-1 replication cycle is divided into early and late phases. The first 
period is characterized by the binding of HIV with the host cellular 
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receptors to viral integration into the human DNA. The second stage 
encompasses the events from the protein translation to the release of the 
mature virions. Initially, viral particles bind to various cell surface binding 
effectors, such as heparin, sulfate proteoglicane, integrin subunit beta 2 
(ITGB2) and nucleolin. This binding facilitates HIV-1 interactions with viral 
receptor on the cells [65]. HIV entry into cells involves viral binding to CD4, 
a receptor expressed on the surface of T lymphocytes (activated T 
lymphocytes represent the main target of HIV-1), monocytes, macrophages 
and dendritic cells [9] and interactions with co-receptors, CCR5 or CXCR4, 
which are both chemokine receptors. HIV-1 variants use either CCR5 or 
CXCR4 and are denoted R5 and X4, likewise some variants use both, 
denoted R5X4.  CCR5 is expressed in memory T lymphocytes, 
macrophages and dendritic cells, and is not expressed in naïve T 
lymphocytes. HIV-1 infection of dendritic cells relies on the capture of the 
virus, resulting in the spread of T lymphocyte infection [66].  Infected 
follicular dendritic cells retain HIV-1 within B cell follicles of lymph nodes 
[9]. For viral entry, the envelope glycoprotein gp120, which form 
gp41/gp120 trimers, binds to CD4 [67]. Viral binding induced 
conformational changes in CD4 and gp120, and additional conformational 
changes occur after the recognition of gp120 by one of the HIV-1 
coreceptors, inducing to the dissociation of gp120 from gp41, and the 
insertion of gp41 into the cellular membrane. This event results in the 
release of the viral core, from viral particles into the target cells after the 
fusion of viral and cellular membranes into the cytoplasm [65]. In the 
cytoplasm, the viral particle is uncoated and RT converts viral RNA into 
linear viral DNA double stranded molecules. Viral DNA associates with viral 
proteins forming PIC complexes of 56 nm diameter composed of PR, RT, 
IN, Vpr, CA, NC and MA proteins [68], [69]. PIC complexes are then 
transported through small channels of the nuclear pore (25 nm of 
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diameter), a process facilitated by mediators. HIV-1 Nef and Vif protein, 
associated with the viral core, and the cellular protein cyclophilin A, 
modulate early events of HIV-1 replication [65]. An early production of viral 
proteins was described even before viral integration [70], [71], [72], [73], 
[74]. Viral replication and viral transcripts production depend on integration 
of HIV-1 DNA into the host DNA resulting in a productive infection [65]. 
Different RNAs include unspliced full-length transcripts, singly spliced 
mRNAs and fully spliced mRNAs. During the late phase of HIV-1, 
transcripts are translated in the cytoplasm, producing both Gag precursor 
(55kDa) protein and GagPol (160 kDa) polyprotein precursor (resulting 
from a ribosomal frameshift events). Gag precursor protein contains MA, 
CA, NC and p66 domains and two spacer peptides SP1 and SP2, while the 
GagPol polyprotein precursor contains the viral protease, reverse 
transcriptase and integrase. The MA domain interacts with 
phosphoinositide phosphatidylinositol-4,5-bisphosphate, a protein in the 
plasma membrane, to drive the Gag domain into the inner leaflet of the 
plasma membrane and to stimulate the incorporation of the Env protein 
into viral particles [75]. The CA induces the multimerization of Gag protein 
during its assembly. NC is critical for the packaging of the viral genome into 
virions. The p6 protein regulates the budding of nascent virions from the 
cell membrane, through a PTAP motif by recruiting Tsg101 and ALIX, 
components of the endosomal sorting complex required for transport 
(ESCRT) apparatus. P6 mediates the incorporation of Vpr protein into 
budding virions. In the cytoplasm, two copies of viral genome are packaged 
into HIV-1 virion core [76]. RNA dimerization occurs in the presence of a 
dimer initiation signal (DIS), present within the 5’ UTR sequence. Different 
conformational changes of the 5ʹ end of the viral genome may favor 
translation or promote packaging [77]. In the plasma membrane the Gag 
protein, full-length RNA and the GagPol precursor assemble into immature 
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viral particle. After the multimerization of Gag molecules, nascent virions 
are released from the membrane of infected cells, budding process, which 
is mediated by the endosomal sorting complexes required for transport 
(ESCRT) machinery. Simultaneously with viral budding, Gag precursor and 
Gag Pol polyproteins are cleaved by the viral protease allowing the 
maturation of the virions and the formation of infective particles.  
 
 
Figure 7:  HIV-1 Life Cycle. After the interaction between Env, CD4 and the co-receptors 
during the fusion of the virus with the cell membrane, the virus entries into the cells, where 
is subjected to uncoated process, reverse transcription, PIC complex formation, 
transcription and protein translation with final assembly, budding and release of the new 
viral particles. (Figure reproduced with permission from Engelman A.et al., 2012 and Nature 
Publishing group) [78] 
1.1.8 Latency  
Viral latency can be classified into pre-integration and post-integration 
latency [79], [80]. Pre-integration latency results from incomplete reverse 
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transcription, decreased entry of the PIC into the nucleus or incomplete 
integration [81], [82]. Pre-integration latency is not involved in the formation 
of long-term latent reservoirs [83]. Post-integration latency results from 
transcriptional silencing, a condition that is influenced by the cellular 
environment at the site of the integration; sequestration of host 
transcription factors like NF-kappaB or NFAT in the cytoplasm, presence of 
repressors of transcription like COUPTF Interacting Protein 2 (CTIP2), 
Negative Elongation Factor (NELF), DRB-Sensitivity Inducing Factor 
(DSIF), T cell factor 4 (TCF-4) associated with beta-catenin molecule and 
the family of tripartite motif-containing (TRIM) proteins, the presence of 
nucleosome (nuc-0 and nuc-1) on the LTR promoter, epigenetic silencing 
of HIV transcription, the sequestration of P-TEFb and the concentration of 
Tat [84], [85]. Histone deacetylation contributes to transcriptional 
suppression, an inhibitor of the histone deacetylase HDAC6 decreases HIV 
latency by increasing the acetylation of histones H3 and H4 in the nuc-1 
region of the HIV LTR [86]. Histone modification is important for HIV-1 
transcription, with histone acetylation resulting in transcriptional activation, 
histone methylation of H3K9, H3K27 and H4K20, is associated with 
transcriptional activation while the methylation of lysine residue 4 H3K4, is 
associated with activation [87]. During latency, the transcription start site of 
the LTR promoter is hyper-methylated at two CpG islands [88].  A defective 
transport of transcripts in the cytoplasm can be correlated with insufficient 
levels of Tat and Rev proteins [89]. Post-transcriptional modification of Tat 
residues influences HIV-1 regulation, with lysine 28 acetylation inducing a 
strong affinity for binding to P-TEFb [90], [91], while   lys50/51 acetylation 
dissociates Tat from TAR. HIV-1 produces viral interference RNAs 
(viRNAs) that can target viral mRNAs (inducing virus latency), cellular 
mRNAs, like CD28, and cellular miRNAs. During HIV-1 infection, Tat and 
Vpr modulate cellular miRNA expression levels in infected cells [92].  
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In ART patients, there exists a low level of viremia derived from low viral 
replication in anatomic sanctuaries inaccessible to the drugs or from viral 
reactivation in resting T cells. Viral reservoirs develop when the 
transcriptionally silent virus persists in some cells or tissues without active 
replication. The main reservoirs are resting central memory T cells (TCM), 
CD45RA- CCR7+ CD27+, (half-life of ~44 months) and translational 
memory T cells (TTM), CD45RA- CCR7-CD27+ [93] [94]. Infected TCM 
cells can originate from infected active T cells that live enough long to 
differentiate to TEM [95], or they can be directly infected or infected prior to 
differentiate in resting T cells. Another source of reservoirs came from 
monocytes and macrophages, naïve T cells and hematopoietic progenitor 
cells (HPC) [96]. Reservoir in the central nervous system (CNS) and the 
gut associated lymphoid tissues (GALT) possesses viral RNA at 5-10 times 
higher levels than found in peripheral blood mononuclear cells [97]. In the 
brain, is possible find infected macrophages after differentiation of 
monocytes that cross the blood brain barrier. Also proviral DNA is present 
in astrocytes and is associated to dementia [98]. The integration of HIV-1 in 
the host is preferentially into introns of active cellular genes. In actively 
infected cells the sense orientation to actively genes comparing to the 
position of viral integrated DNA, may have a repressive role in viral 
transcription comparing than antisense orientation. Substances like 
phorbol, prostatin or methamphetamine, inihibitor of Wnt, histone 
deacetylase inhibitors (HDACI, valproic acid or SAHA) and IL-7 can 
activate HIV-1 expression [99].  
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1.2 HIV-1 treatment 
 
1.2.1 Antiretroviral Therapy 
Antiretroviral therapy was developed in the late 1990s and changed the 
outcome of the HIV-1 epidemic. Highly active anti-retroviral therapy 
(HAART) became available in 1995. US and European regulatory agencies 
recommend 25 unique antiretroviral drugs specific against different steps of 
the HIV-1 life cycle. Antiretroviral therapy decreases the level of the viral 
load below the limit of detection within the initiation of the treatments [3]. 
Only a small percentage of HIV-infected patients in the world have access 
to HAART. Patients showing a decreased of viral load and an achieve of 
normal CD4+ count have an expectancy of life close normal life [100], but 
interruption of ART leads viral rebound, active replication and progression 
towards AIDS. During HAART there is the potential of the emergence of 
HIV-1 variants which are resistant to anti-retroviral drugs [3]. Different 
classes of drugs used in ART therapy include nucleoside reverse 
transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase 
inhibitors (NNRTIs), integrase strand transfer inhibitors, protease inhibitors 
and entry inhibitors. NRTIs are analogues of natural nucleosides and 
nucleotides blocking HIV-1 reverse transcriptase activity, but are 
preferentially incorporated into HIV-1 DNA and determine the termination 
of HIV synthesis. Drugs recommended in this class are tenofovir, abacavir, 
lamivudine, emtricitabine. Integrase strand transfer inhibitors avoid viral 
integration and are well tolerated and safe. NNRTIs inhibit reverse 
transcriptase binding to a pocket near the active site of the enzyme. 
Protease inhibitors block the activity of the protease in the late state of HIV-
1 replication avoiding the maturation of the virus, these drugs are usually 
administrated with two nucleoside analogues. Entry inhibitors prevent the 
entry of the virus in the cells, by binding to CCR5 or the virus. 
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HIV-1 reservoirs are resistant to the action of antiretroviral drugs, thus 
providing a source for viral reactivation after ART interruption (viral 
rebound). The use of other strategies for the control the HIV-1 viral load 
and of the progression towards AIDS in absence of antiretroviral therapy 
(functional cure) has been proposed. One such proposed mechanism is a 
sterilizing cure, in when the aim is to eradicate the virus from all cells in the 
body, either actively or latently infected. Currently, no sterilizing cure 
method has proven successful. 
                   
Figure 8: HIV-1 RNA copies/ml in the plasma in patients treated with antiretroviral 
therapy. The first phase is characterized by a rapid decline of viral load due to the short haf 
life of the infected CD4+ T cells. The second phase is characterized by the loss of infected 
CD4+T cells, macrophages amd dendritic cells. In the third phase a low level of viremia, 
under the limit of detection is manteined by HIV-1 reservoirs. Viral rebound is observed after 
antiretroviral therapy interruption. (Figure reproduced with permission from Van Lint C. et 
al., 2013 and open access Retrovirology Journal) [99] 
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Figure 9: Global Incidence of HIV-1 infected patients under ART therapy between 
2010-2015 (Figure created using the ufficial data from UNAIDS, special analysis, 2017) [7] 
1.2.2 Vaccines  
The genetic diversity of the HIV-1 genome and the difficulty to develop 
highly immunogenic antigens decreases the probability of developing a 
candidate vaccine with high efficacy. Numerous neutralizing antibodies act 
against a conserved region of HIV envelope in 90 % of the HIV strains 
when administered as passive immunoprophylaxis. A previous trial used an 
adenovirus vector for vaccine strategy, however this strategy resulted in an 
increased rate of HIV infection in people with pre-existing antibodies to the 
adenovirus used [101]. The RV144 trial completed in Thailand in 2013 
involved 16402 people with a high risk for HIV. The vaccination series used 
four immunizations with ALVAC Vcp1521, which express Gag/Pro and Env 
antigens. This treatment was followed by two booster injections with a 
recombinant gp120 formulated with alum and is the only clinical trial 
showing positive results with a 31 % reduction in HIV acquisition [103]. 
1.2.3 Transplantation of Hematopoietic Stem Cells 
Latently infected cells constitute a viral reservoir in circulating blood, CNS, 
bone marrow and gut associated lymphoid tissue [103]. New strategies for 
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a sterilizing cure were developed after the case of the “Berlin patient”, an 
HIV-1 patient that received an allogenic stem cells transplant to treat acute 
myeloid leukemia from a donor with a mutated CCR5 gene. The donor 
mutation was CCR5∆32 homozygous, a deletion of a 32-base pair region 
in the receptor gene that confers HIV-1 resistance due the production of an 
inactive CCR5 receptor. Homozygous patients with this mutation are 
completely protected by HIV-1 infection, while heterozygous patients 
present a slower progression of the disease [104]. After transplantation, the 
Berlin patient presented with an undetectable viremia level for more than 9 
years without ART therapy. Later, two other HIV-1 patients with Hodgkin’s 
lymphoma who were heterozygotes for CCR5∆32 received transplantation 
of hematopoietic stem cells from donors with wild type CCR5, but viral 
rebound was observed after 12 and 32 weeks of interruption of ART 
therapy [105]. 
 
1.2.4 Shock and Kill Therapy Approach  
One strategy proposed to eradicate HIV-1 reservoirs is the “purging 
strategy” [106] or shock and kill therapy. The use of latency reversing 
agents (LRA) which reactivate viral transcription in latent cells to increase 
viral production (shock), is followed by infected cell death and recognition 
by the immune system (kill) in combination of ART to prevent new 
infection. Different LRA molecules have been used in vitro and ex vivo. 
Most commonly HDAC inhibitors such as valproic acid (VPA), an 
antiepileptic agent that acts against HDAC I and II, trichostatin A (TSA), 
suberohylanilide hydroxamic acid (SAHA), Panobinostat (LBH-589), 
Benzamides, and cyclic tetrapeptides. Other molecules including histone 
methyltransferase (HKMT) inhibitors, PKC agonists or NF-KB are used to 
promote transcription [103]. This approach has limitations; such as low 
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efficiency to induce latency cells, no specificity effects and toxicity [107]. 
Due to these limitations, other strategies are required to eradicate HIV-1, 
including proposed gene editing strategy. 
1.2.5 Gene Therapy Strategies 
Different approaches for gene editing involve either RNA based strategies, 
such as ribozymes, antisense RNA, small interfering RNA, or protein-based 
strategies, such as meganucleases, zinc finger nuclease (ZFN), 
transcription activator like effector nuclease (TALEN), clustered regular 
interspaced repeats (CRISPR system).  
1.2.6 Cre recombinase  
The first gene editing approach used was Cre recombinase from the P1 
bacteriophage, which induces events of recombination between 2 LoxP 
sites [108]. Through substrate-linked protein evolution (SLiPE) it is possible 
to place a region of interest adjacent to the recombinase coding region 
[109]. This system was used to target the LTR region in latently infected 
cells, obtaining efficient excision of the integrated HIV proviral DNA [110]. 
Mariyanna et al. [111] describes Tre-recombinases expressed in bacteria 
targeting the protein transduction domain (PTD) of HIV-1 Tat. These 
recombinases can induce recombination activity of HIV-1 LTR sequences 
in human HeLa cells and induce proviral DNA excision from chromosomal 
integration sites. Hauber et al. [112] used a self-inactivating lentivirus to 
deliver a Tre-recombinase in primary CD4+ or CD34+ cells engrafted in 
humanized Rag2−/−, γ−/− mice inducing HIV-1 provirus excision. A 
limitation of the Tre-recombinase system is limited specificity, currently only 
targeting HIV-1 subtype A isolates. Further studies by Karpinski [113], 
developed a new recombinase (Brec1) effective against 34 base pair of 
LTR sequences of multiple HIV-1 strains and subtypes. The Brec1 
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recombinase resulted in excision of integrated HIV-1 provirus in vitro and 
in vivo, including in humanized mice engrafted with patient cells. 
 
1.2.7 Homing endonucleases   
Homing endonucleases are sequence-specific endonucleases of the 
meganuclease family that target a DNA sequence of 16-30 base pairs 
[114]. The DNA binding site and the nuclease site are confined to the same 
domain. Homing endonucleases were used in lentiviral vectors to target the 
integrated HIV-1 provirus DNA. An important limitation of this approach is 
the large size and the low degree of specificity [115]. 
 
1.2.8 The Zinc-Finger Nuclease (ZFN) 
Zinc-finger nucleases (ZFN) are engineered nucleases containing specific 
transcription factors that recognize target DNA through zinc finger motifs 
and a non-specific endonuclease domain Fok1. The binding of the paired 
zinc finger protein with the Fok1 domain induces activation of the ZFN, 
leading to double stranded DNA breaks in the target sequence [116]. Each 
finger of this protein recognizes a specific sequence of three nucleotides. 
ZFNs technology have been used to modify the genome of plants, animals 
and humans. Different laboratories used ZFNs protein to target the cellular 
CCR5 and CXCR4 receptors in infected CD4+ T cells [117], [118], [119], to 
target M tropic HIV-1 strains (R5 viruses), and T tropic HIV-1 strains (X4 
viruses). Holt et al. [120] engineered CCR5 knockout human cells and 
engrafted them into immunodeficient mice. These mice showed a rapid 
selection of CCR5-/- cells and a consequent reduction of HIV-1 level 
compared to the negative control. Maier et al. used an adenoviral vector 
encoding CCR5-specific ZFN to express the modified CCR5 in stimulated 
CD4+ T cells [121]. Tebas et al. used this technology to infuse in HIV-1 
patients autologous CD4+ T cells after disruption of CCR5. Six of the 
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twelve patients that suspended ART showed later viral rebound suggesting 
that this technology delays disease progression yet isn’t a permanent cure 
[122].  Li et al. [123] used a recombinant adenoviral vector for CCR5-ZFN 
to engineer CD34+ hematopoietic stem/progenitor cells and engraft them 
into a humanized mouse model, supporting the idea that this strategy 
allows the selection of the mutated cells by the same virus. Yi et al. [124] 
reported suppressed viral replication in CD4+ cells of HIV-1 positive 
patients engrafted in mice and transduced with a non-integrated lentivirus 
vector inducing expression of CCR5-ZFN. Yao et al. [125] showed the 
capacity of ZFN engineered CCR5 pluripotent stem cells (hiPSCs) to 
differentiate into CD34+ cells in vitro, suggesting the possibility of 
modifying patient-specific stem cells to treat of HIV infection. Yuan et al. 
[126] engrafted ZFN-modified CXCR4 CD4+ T cells in HIV-1-infected NSG 
mice, resulting in resistance to HIV-1 CXCR4strain. Didigu [127] used 
ZFNs to modify CCR5 and CXCR4 in human CD4+ T cells and infuse them 
into a humanized mouse model of HIV-1 infection, resulting in resistance to 
HIV-1 CCR5 and CXCR4 tropic strains.  
 
 
Figure 10: Zinc Finger Nuclease Model. This model is characterized by two domains; a 
DNA binding domain and a DNA cleaving domain [128] 
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1.2.9 Transcription Activator‑Like Effector Nucleases (TALEN) 
Transcription like effector nucleases (TALEN) are produced by the bacteria 
Xanthomonas spp. to modify the transcription of the host plant cells. This 
system contains a FokI aspecific nuclease domain and a TALE-derived 
DNA binding domain with a conserved 33-35 amino acid repeats [129]. The 
number of repeats determines the length of the DNA target. Each repeat of 
the TALE domain binds a specific single nucleotide. The DNA specificity 
depends on two hypervariable residues in position 12 and 13 of each 
repeat. The presence of Asn/Asp is specific for cytosine, Asn/Gly is specific 
for thymine, Asn/Asn for guanine and His/Asp for cytosine. TALENs have 
been used for the therapy of HIV-1, to target the CCR5 gene, the 
epithelium-derived growth factor and LEDGF/p75 [130]. TALENs and zinc 
fingers both induce a 45 % disruption of the CCR5 gene, but TALENs are 
less cytotoxic, more specific (each repeat recognizes one nucleotide 
instead three for ZFN), possess less off target effects and can target 
methylated DNA, resulting in specific targeting HIV-1 provirus [131].  
Limitations of TALENs include the large size of the construct which 
constitutes an issue for efficient delivery [130]. Ru et al. [132] created a 
Tat-TALEN protein, complex delivered by a cell penetrating peptide that 
induced a 5% modification rate in the CCR5 gene of human-induced 
pluripotent stem cells. Mock et al. [133] used non-integrated lentivirus to 
deliver CCR5-specific TALENs in different cell lines and in T cells, 
obtaining >50% CCR5 knockout and low off-target activity. Fadel et al. 
[134] used the TALEN technique to target the human PSIP1 gene, which 
encodes the cellular protein LEDGF/p75, an HIV-1 integration cofactor. 
Knockout of PSIP1 gene was due to made by deletion of the whole gene or 
by deletion of the integrase binding domain, resulting in inhibition of HIV-1 
integration and viral replication in Jurkat and HEK293 T cells. Ebina et al. 
[135] used a lentiviral vector to deliver HIV LTR TALEN protein in a T 
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cellular line obtaining an excision of >80% of HIV-1 proviral DNA. Strong 
et al. [136] used HIV TAR TALEN protein to induce indel mutations in HIV-
infected cells, resulting in a loss of Gag production. 
 
 
Figure 11: TALEN Model System. Schematic representation of the TALEN model system, 
showing the presence of TALE repeat domains and the Fok1 nuclease domain, which 
provides the gene editing capability (Figure reproduced with permission from Joung JK et 
al., 2013 and Nature Publishing Group) [137] 
 
1.2.10 Double Strand Break (DSB)  
The excessive time and cost for production of engineered ZFNs and 
TALENs protein resulted in the development of an easier and more 
powerful strategy of gene editing called clustered regulatory interspaced 
short palindromic repeat system (CRISPR). This mechanism utilizes the 
adaptive immune system of archaea and of bacteria and was adapted to 
mammalian genome editing. CRISPR loci contain a clustered set of 
CRISPR-associated (Cas) genes and a CRISPR array consisting of a 
series of direct repeats interspaced by specific sequences, called spacers, 
that recognize foreign sequences, a protospacer, via Watson-Crick base 
pairing [138]. Generally, genome engineering strategies have been used to 
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induce double stranded breaks (DSB) at a DNA target site. The DSBs 
produced by these gene editing molecules are repaired by homology-
directed repair (HDR) or non-homologous end joining (NHEJ) system. HDR 
can utilize a donor template, allowing the introduction of specific point 
mutations or the insertion of specific sequences through recombination 
between the donor template and the DNA target. The system NHEJ can 
introduce mutations like deletions and insertions (indels) that may results in 
frameshifts or production of stop codons disrupting the open reading frame 
(ORF) of the target gene and the excision of the section of the DNA 
between the DSB when multiple gRNAs are employed, resulting in a loss of 
gene function. The frequencies of these mutations is generally between 1% 
- 50 %, yet can be higher depending on the system. Unlike the use of 
monoclonal antibody or RNA interference systems, NHEJ-mediated system 
induces permanent modification on genome avoiding periods of repeated 
treatments [139]. 
 
 
Figure 12: Induction of Double Strand Breaks after gene editing. Gene editing through 
either zinc finger nucleases, TALEN or CRISPR treatments results in double-stranded DNA 
breaks, which is repaired by either cellular homologous recombination or non-homologous 
end joining DNA repair. Generally, homologous recombination is preferred when the goal is 
gene replacement while non-homologous end-joining is preferred when the goal is 
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mutagenesis of a target gene (Figure reproduced with permission from Khalili K. et al., 2015 
and Springer) [139] 
 
1.2.11 CRISPR SYSTEM 
In 1987 Nakata et al., [140] described the presence of 29 nucleotide 
repeats between five 32 nucleotides no repetitive sequences in Escherichia 
coli. These repeats were classified belonging to a unique category of 
clustered repeat elements found in the >40 % of bacteria and 90 % of 
archea [141]. In 2002 Jansen and Mojica [142], [143] denoted CRISPR to 
describe all microbial genomic loci containing interspaced repeat elements.  
In the same year, Jansen described the presence of cas genes adjacent to 
the interspaced repeats. The CRISPR system is classified into three types 
based on difference in the cas genes [144], [145]. Type I and III contain 
more Cas genes compared to type II and form complexes with crRNA 
called CASCADE complexes and Cmr or Csm RAMP complexes. CRISPR 
arrays are transcribed in crRNAs containing spacers that direct the activity 
of the nuclease to the target, containing by RNA and DNA for CRISPR type 
III [138], or DNA for types I and II. In type II, the processing of crRNA into 
mature crRNAs depends on the presence of a trans-activating crRNA 
(tracrRNA) that hybridizes with the crRNA, together with Cas9 and the 
endogenous RNase III, the crRNA processes the pre-crRNA into mature 
RNA [146]. Type II CRISPR, is present only in bacteria and can be 
classified into three subtypes (IIA-IIC) based on different Cas genes. Type 
IIC contains cas9, cas1 and cas2 genes. Types IIA and IIB contain two 
additional genes, csn2 or cas4 genes respectively [147]. In the latest 
classification, CRISPR can be divided in two classes, class 1 (that includes 
the type I and III) which uses several Cas proteins and crRNAs and class II 
(CRISPR type II and of type V), which employs a single component Cas 
protein and crRNAs [148]. CRISPR type II uses the Cas9 protein, while the 
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type V uses another protein of 1300 amino acid called CRISPR from 
Prevotella and Francisella 1 (Cpf1). Cpf1-associated CRISPR arrays differ 
from the type II by three important characteristics: pre-crRNA is processed 
into mature crRNAs without the action of the tracrRNA, the presence of a T 
rich PAM sequence preceding the target sequences is required instead of 
a G rich PAM sequence following the DNA target in the type II, and this 
protein induces DSB with four or five nucleotides 5’ overhang [149]. 
Moineaua at el discovered that in Streptococcus thermophilus, Cas9 (also 
called Cas5, Csn1 or Csx12) is the only Cas gene able to induce DNA 
editing [150]. Cas9 protein contains two nuclease domains, RuvC (divided 
in 3 domains, RuvC I close the N terminal of Cas9 protein and RuvCII/III 
close to the HNH domain) and HNH (single nuclease domain), each of 
which nicks a strand of DNA to generate a blunt-ended DSB. The structure 
of Streptococcus pyogenes Cas9 (spCas9) was deeply characterized, 
revealing the presence of a central channel that houses the RNA-DNA 
target hetero-duplex after rearrangements of Cas9 binding crRNA and 
tracrRNA [151]. Cas9 structure analysis revealed the presence of two 
lobes, an alpha elical recognition (REC) lobe that facilitates binding with 
the target sequence and a nuclease lobe that contains HNC and RuvC 
domains and a PAM interacting (PI) C terminal region. When Cas9 is 
unbound, the active site of HNH domain is blocked by the RuvC domain 
and the binding RNA-DNA is inhibited by the C-terminal domain. The 
SpCas9 REC2 domain is poorly conserved in orthologs, allowing the 
production of Cas9 mutants that are highly compact with increased 
efficiency [152]. Different bacteria are characterized by several Cas9 with 
similar structure but different size ranging from 900 to 1600 amino [145]. 
Type II CRISPR requires the presence of protospacer adjacent motifs 
region (PAMs) at the 3’ end of the target region, sequence specific of each 
Cas9 ortholog for DNA cleavage [153]. SpCas9 recognizes both 5’NGG 
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PAM and 5’NAG PAM sequences, with the complexity of the PAM regions 
determining the DNA targeting space of Cas9 [138]. The choice of the 
promoter, either U6 or T7, to express gRNAs influences the target 
sequence by requiring a G or GG at 5’ end of the spacer respectively. The 
Cas9-crRNA-trRNAcomplex first associates with the PAM sequence, then 
Cas9 initiates the separation of DNA strand with unknown mechanism and 
edit the DNA target.  CRISPR types I and III require the presence of 
mismatches at the 5’ end of the crRNA and the target sequence to initiate 
gene editing [154]. In 2012, a study demonstrated the ability of purified 
Cas9 from Streptococcus thermophilus or Streptococcus pyogenes (Sp) to 
edit DNA targets in the presence of crRNAs [155]. CRISPR type II utilizes 
the combination of SpCas9 and guide RNA (gRNA), which is the fusion of 
a crRNA and a tracrRNA.  
Cas9 is a universal nuclear which has been adapted for gene editing in 
many organisms, including bacteria, yeast, fruit flies, zebrafish, mice, rats, 
monkeys, and human cell lines [138]. Following administration of Cas9, 
target DNA is cleaved, resulting in a DSB three to four nucleotides 
upstream of the PAM sequence. In mammalian cells, CRISPR-mediated 
gene editing requires the use of engineered gRNAs, which fuse a crRNA 
and a tracrRNA containing a roughly 20 nucleotide guide sequence to 
ensure DSB at specific genomic sites. Likewise, a dual gRNA system can 
be utilized, containing a second stem loop which increases the stability of 
the gRNA compared to single gRNAs.  
The use of Cas9 as a gene editing strategy for human patients has 
unlimited potential as both a therapeutic agent and a genome editing 
agent. Cas9 gene editing has been proposed for the treatment of multiple 
monogenic recessive disorders resulting from loss-of-function mutations, 
such as cystic fibrosis, sickle-cell anemia, or Duchenne’s muscular 
dystrophy. Likewise, Cas9 has been proposed to treat polygenic disorders 
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and dominant-negative disorders, including diabetes, heart disease, 
schizophrenia, autism, transthyretin-related hereditary amyloidosis and 
dominant-negative forms of retinitis pigmentosum [138].  
However, the therapeutic potential of CRISPR is still in its infancy. The first 
clinical trial using CRISPR technology was in 2016 at Sichuan University in 
Chengdu, China. In this trial, peripheral blood lymphocytes were collected 
and programmed cell death protein 1(PD-1) was knocked out by CRISPR-
Cas9 in vitro, after which knockout cells were clonally expanded and 
infused into the patient. This trial remains underway, with completion and 
publication being expected in April 2018 [156]. Various studies have 
demonstrated off-target Cas9 binding, however, this binding does not 
necessarily induce cleavage at all off-target sites. Currently, several 
software programs, including DNA2.0 CRISPR gRNA design tool, E-
CRISP, sgRNAcas9 software package, CasOFFinder, and CasOT, are 
offered to assist with gRNA design to limit off-target binding [139]. 
Generally, mismatches in the target sequence are better tolerated at the 5’ 
end of the 20-nucleotide gRNA spacer region than at the 3’ end [157], 
[158], [159]. Experimental analysis of gRNA specificity, off-target DNA 
binding sites, and the presence of indel mutations can be assessed 
through multiple assays, including the T7 endonuclease I mutation 
mismatch assay and deep sequencing analysis. To limit off-target binding, 
gRNAs can be designed to target GC-rich domains, thus increasing binding 
specificity. Other methods to decrease off-target binding include reducing 
gRNA concentration and Cas9 expression, using Cas9 variants or modified 
gRNAs with truncated 3’-ends or with two extra 5’-guanines, or by using 
gRNAs with a shortened 5’-end for the complementary region [160]. 
Another method to reduce off-target effects is to use nickase variants, 
produced by inactivating one of the two Cas9 nuclease domains via the 
induction of point mutations, which results in the stronger stimulation of 
40 
 
high fidelity homology directed repair. To improve on this method, a paired 
nickase system was recently developed which inactivates one of the two 
nuclease domains of SpCas9 [161]. This system utilizes two gRNAs and 
two monomeric nickases, resulting in single-strand DNA breaks on 
opposite DNA strands, which increases the editing specificity by up to 
1500-fold [162]. Wild-type Cas9 can be catalytically inactivated (dCas9) 
and subsequently directed by gRNAs to a targeted DNA sequence, 
resulting in transcriptional suppression due to Cas9-mediated steric 
hindrance of the RNA polymerase machinery [163]. This method is called 
CRISPR-based interference, CRISPRi, in which direct tethering of the 
catalytically inactivated Cas9 to a transcriptional repressor domain induces 
epigenetic silencing [164], [165]. The fusion of inactive Cas9 to either 
transcription activation domains, such as VP16/VP64 or the p65 subunit, or 
to transcriptional repressor domains allows targeting of endogenous 
transcription. For transcriptional regulation to occur, two RNA-guided Cas9 
monomers must bind targets on opposite DNA strands that are separated 
by 14-17 base pairs or by 25 base pairs, depending on the system being 
used. The necessity of both Cas9 monomers binding to a specific 
sequence serves to significantly increase targeting specificity. This 
transcriptional regulation can be modified by altering the presence of 
multiple sgRNAs and has been shown to function in bacteria, mice cells, 
and human cells [165], [166], [167].  
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Figure 13: Cas9-gRNAs Interactions. The gRNA is characterized by a CRISPR RNA and 
a trans activating crRNA. (FIgure reproduced with permission from Khalili K. et al., 2015 and 
Springer)) [139] 
1.2.12 CRISPR/Cas9 Delivery 
Currently, delivery of CRIPSR/Cas9 into cells can be accomplished by a 
wide variety of mechanisms, including both viral and non-viral delivery 
methods, which deliver the CRISPR complex into cells in the form of DNA, 
RNA, or as a protein/RNA complex. Viral delivery methods include 
lentiviruses, baculoviruses, and recombinant adeno-associated viruses 
(rAAV). AAV-based vectors are advantageous due to low immunogenicity 
and multiple administration routes, including intranasal and intratracheal 
administration and by stereotactic, intravenous, intraperitoneal, and 
intramuscular injections. AAVs can transduce both dividing and non-
dividing cells without host-genome integration. However, the major 
limitation of AAVs is the limited packaging capacity of 4.7 kilobases. Due to 
this property, many AAV-based delivery systems utilize Cas9 from 
Staphylococcus aureus (saCas9) as opposed to the traditional 
Streptococcus pyogenes due to the small size of saCas9. While SaCas9 is 
smaller than SpCas9, it requires a longer PAM sequence for specific 
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targeting [168]. There are two types of safe lentiviruses vectors that can be 
used for CRISPR delivery, which are self-inactivating replication 
incompetent or integrase defective lentiviruses. This delivery system allows 
for transient CRISPR expression and can be used to transduce both 
dividing and non-dividing cells. The major advantage of lentiviruses is their 
high capacity for packaging, allowing for the use of large inserts [139]. 
There are many options in terms of non-viral delivery mechanisms, 
including cationic polymer polyethyleneimine (PEI), liposomes, lipid 
nanoparticles, virus-like particles, bacteriophages, and self-assembled 
DNA nanoparticles. Recently, the use of ligand functionalized nanoparticles 
has been prominent due to their ability to bind endothelial cell receptors, 
allowing efficient transmigration across the blood-brain barrier (BBB) from 
the periphery into the central nervous system. Another recent 
advancement has been the use of electric nanoparticles to mediate 
crossing of the BBB in combination with a magnetic field gradient [169], 
[170]. 
1.2.13 CRISPR/Cas9 system for HIV-1 Genome Editing 
CRISPR/Cas9 gene editing can be used to impact either host cells to 
inhibit viral infection, either through cellular entry or other mechanisms, or 
to directly affect the virus through various mechanisms. The first 
application of the CRISPR/Cas9 system against HIV was in 2013 by Elbina 
et al, [171] in which it was used to eliminate the HIV provirus from T-cells 
by targeting the TAR region in the R region and the NF-κB binding 
sequence in the U3 region. This study revealed that indel mutations can 
inhibit active provirus expression and decrease latent virus reactivation. 
One study in which CRISPR/Cas9 gene editing was used to target host 
cells was completed by Hou et al, in which they showed that targeting the 
HIV coreceptor CXCR4 induced the receptor expression by 30% on human 
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T-cells by treatments with Cas9, thus inducing HIV-1 resistance by 
blocking cellular entry [172]. Another follow up study utilized Cas9/sgRNA 
ribonucleoproteins (Cas9 RNPs) treatments to decrease CXCR4 
expression by 40% in human primary T cells to induce HIV resistance 
[173]. After the Berlin patient results demonstrated that CCR5Δ32 mutation 
inferred HIV-1 resistance, CRISPR/Cas9 gene editing was used to target 
the CCR5 coreceptor to inhibit HIV infection. Ye et al treated pluripotent 
stem cells (PSCs) with CRISPR/Cas9 constructs to induce CCR5Δ32 
deletion, obtaining roughly 100% efficiency for one allele and up to 33% 
efficient for the deletion of both alleles, obtaining HIV-resistance in cells 
derived from the treated induced PSCs [174]. Wang et al used a lentiviral 
vector approach, targeting three sites of the CCR5 gene in a human CD4+ 
T-cell line, obtaining cells which were resistant to HIV R5 infection, yet this 
gene disruption approach failed in human primary T-cells [175]. Li et al. 
used an adenoviral approach to target and destroy CCR5 in TZM-bl cells 
and CD4+ T-cells [176].   
In addition to modifying host cells to resist HIV infection, CRISPR/Cas9 can 
be used to directly target HIV. Zhu et al targeted three sites in the HIV LTR, 
five sites in pol, and two sites in rev to eradicate HIV provirus in Jurkat 
cells, resulting in a 20-fold reduction of HIV production [177]. Additionally, 
CRISPR/Cas9 has been used in combination with the “shock and kill” 
approach to potentially eradicate the virus from latent sites of infection. 
Zhang et al used catalytically inactivated Cas9 transcription activator fusion 
protein complexed with sgRNA to activate HIV latent reservoirs in multiple 
cell lines such as TZM-bI epithelial, Jurkat T cells and CHME5 microglial 
cells. The sgRNA targeted twenty different sites within the U3 LTR region, 
resulting in accumulation of viral proteins and cell death [178]. The results 
from this study resulted in the NF-κB binding site being identified as the 
most highly efficient target site to target when activating HIV in latent cells, 
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which was bolstered by results from Saayman et al. [179]. Hu et al. used 
lentiviruses vectors containing Cas9 or gRNAs A/B targeting the U3 region 
in both LTRs sequences. This technology asses the ability of the gRNAs to 
excise a 9709-base pair region of the integrated virus from the genome of 
latently infected microglia, promonocytics and T cells obtaining a decrease 
of viral expression. This study showed that the presence of multiple gRNAs 
and Cas9 in the cells can prevent new HIV-1 infection through a rapid 
elimination of viral DNA. This approach can be used like a gene editing 
based vaccine, likewise further investigation is necessary to assess this 
system in latent reservoirs cells and analyze in animal model the presence 
of off target and the ability to eradicate viral reservoir in vivo [180]. When 
CRISPR/Cas9 gene editing was proposed for the treatment of HIV, one 
potential outcome was the mutation of variants resistant to targeting, called 
escape variants. The presence of HIV-1 escape variants was shown by 
Wang et al. [181]. These variants, produced by NHEJ repair, contained 
mutations close to the Cas9 cleavage site, rendering the viral variants 
immune to gene editing using that system, data that was confirmed by 
Yorder et al [182]. A proposed method to bypass the creation of escape 
variants is the use of several gRNAs which direct Cas9 to different regions 
of the HIV genome. This mechanism creates several excision points in the 
proviral genome, allowing for the cleavage of escape variants at one 
cleavage site by targeting a secondary or tertiary cleavage site, thus 
eliminating the development of HIV escape variants following 
CRISPR/Cas9 treatment. 
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Table 2: CRISPR/Cas9 Studies Related to HIV-1 Treatment. Table shows various studies 
utilizing CRISPR thereapies for HIV-1 treatment and potential eradication. The target gene 
is described in the region of interest and the tested model, either animal models or human 
cells, is denoted. Additionally, the delivery system, either adenoviruses, adeno-associated 
viruses, lentiviruses, or transfection methods, is denoted.  
 
 
 
Region of interest Target Delivery Reference 
LTR (R and U3)  T cells transfection [171] 
LTR (U3) TZM-bI/U1/J-Lat Transfection [180] 
 
CCR5 
HEK 293 T, HeLa, 
NCCIT, human 
embryonic stem cell 
 
transfection 
 
[183] 
CCR5 Induced PSCs transfection [174] 
 
LTR (U3) 
TZM-
Bi/Jurkat/CHME5 
microglia cells 
 
lentivirus 
 
[178] 
LTR/POL/REV Jurkat cells transfection [177] 
CCR5 TZM-Bi/ CD4+T Adenovirus [176] 
CXCR4 Human CD4+T cells lentivirus [172] 
CXCR4 T cells transfection [173] 
5’LTR Tcells transfection [179] 
LTRs Human CD4+T 
cells,2D10 
lentivirus [184] 
LTR TZM-Bi/Jurkat cells lentivirus [185] 
LTR/GAG Tg26 mice AAV  [186] 
CCR5 HUMAN CD4+ T 
cells 
lentivirus [181] 
CXCR4 B cells transfection [187]  
LTR/GAG/POL Tg26/humanized 
mice 
AAV [188] 
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2. Aim of the Study 
Throughout the world, HIV-1 infects more than 36.9 million people, including 
2.6 million children [7]. Currently, the primary therapeutic regiment is 
treatment with antiretroviral agents, called antiretroviral therapy (ART). 
During ART, HIV persists in the body as a provirus in latently infected cells, 
resulting in a chronic latent condition. As treatment with ART does not 
eliminate HIV it is not considered a curative strategy [3]. Current studies 
have focused on developing treatments which can target both actively and 
latently infected cells to eradicate the virus. Recently, CRISPR-Cas9 has 
become the predominant strategy for gene editing and elimination of 
integrated proviral DNA. The CRISPR/Cas9 system consists of a nuclease 
(Cas9) and a guide RNA (gRNA) that directs Cas9 activity to specific DNA 
sequences to induce double strand breaks resulting in replication-defective 
virus [139]. To deliver the CRISPR/Cas9 system to cells either lentiviruses, 
adenoviruses or adeno-associated viruses (AAV) can be used. To 
investigate the potential of therapeutic potential of the CRISPR/Cas9 
system, our laboratory utilized in vitro and in vivo approaches:  
 
a) Studies in vitro of an inducible system of spCas9 activated by Tat, 
targeting LTRs HIV-1 regions and delivered by lentiviral vectors 
b) Studies in vivo with the shorter saCas9 targeting LTR and Gag HIV-1 
regions and delivered by AAV9 vectors in transgenic mice and rats 
c) Studies in vivo with the shorter saCas9 targeting LTR and Gag HIV-1 
regions and delivered by AAV9 vectors in humanized mice  
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3 Materials and Methods 
 
3.1 Plasmid Preparation 
The vectors px260-LTR-Cas9 containing the full length LTR (-456/+66) 
and the truncated LTR promoter sequences (-120/+66 or -80/+66) were 
cloned by PCR using pNL4-3 HIV vector (NIH AIDS Reagent Program 
#114) as the template and the primers described in Table 6. The PCR 
products were subcloned into the pCR™2.1-TOPO® TA vector (Life 
Technologies, CA) and high copies of plasmid DNA were obtained after 
transformation of the ligation product into the DH5α strain of 
Escherichia coli (Invitrogen, USA). Plasmid DNA was extracted from 
bacteria using the Qiagen Plasmid Minikit (Qiagen, Germany). Purified 
DNA was digested with KpnI or XbaI and NcoI restriction enzymes and 
ligated into pX260-U6-DR-BB-DR-Cbh-NLS-hSpCas9-NLS-H1-shorttracr-
PGK-puro plasmid (Addgene #42229) replacing the Cbh promoter with 
LTR promoters.  
 
In the LentiCas9-Blast plasmid (Addgene #52962) the EFS promoter was 
replaced with the LTR promoter. Briefly, LTR promoter regions were 
amplified using the primers listed in table 6, subsequently subcloned into 
the TA vector and digested with NheI and XbaI restriction enzymes, 
finally ligated with Nhe I and XbaI digested lentiCas9Blast. The correct 
replacement of the promoter sequence was confirmed by DNA sequence 
analysis (Genewiz, USA) using BLAST from the NCBI.  
 
pKLV-U6-LTR A/B-PGKpuro2ABFP and pCMVTat86 plasmids were 
previously described [184, 189]. pKLV-U6-LTR A and B-PGKpuro2ABFP 
plasmids contain a gRNA expression cassette under the control of U6 
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promoter. PcDNA3.1 (#V79020) was bought from Invitrogen (Carlsbad, 
USA).  
 
px601-AAV-CMV:NLS-saCas9-NLS-3xHA-bGHpA:U6:Bsa1-SgRNA 
(Addgene #61591). Briefly pX601 was donated by Feng Zhang and was 
used for cloning the gRNAs LTR1 and GagD sequences. px601 was 
digested with BsaI, treated with calf intestinal alkaline phosphatase (CIP) 
and gel purified using QIAquick Gel Extraction kit (Qiagen, Germany). A 
pair of oligonucleotides specific for LTR and Gag regions (Table 6) were 
annealed, phosphorylated, and ligated with the linearized vector. To 
clone the GagD sequence into the pX601 vector containing the LTR1 
gRNA, the vector was digested with EcoRI and KpnI and the linearized 
product was purified and ligated with the PCR product of Gag region 
using px601 containing GagD gRNA as template and T795 and T796 
primers containing the restriction site for EcoRI and KpnI.  
T795: ATTACGCTTAAGAATTCCTAGAGC 
T796: ggaaataggccctcagACTAGGGGTTCCTGCGGCCGCAAA 
 
Clones were tested using BamHI or EcoRI +NotI and sequenced. 80 ug 
of a positive clone was sent to the Penn Vector Core, (Perelman School 
of Medicine, University of Pennsylvania) for the packaging in AAV 9 
serotype.  
 
3.2 Cell Culture  
TZM-bl cells are HeLa cells stably expressing CD4, CCR5, CXCR4 and 
luciferase and b-galactosidase reporter genes under the control of the 
HIV-1 LTR promoter. The TZM-bl cell line, obtained from the National 
Institutes of Health (NIH), was maintained with Dulbecco’s Modified 
Eagle Medium (DMEM), (Thermo fischer scientific, USA), supplemented 
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with 10% heat inactivated Fetal Bovine Serum (FBS), (Thermo fischer 
scientific, USA) and gentamicin (10 μg/ml). 
 
Jurkat Clone E6-1 cells were obtained from ATCC (TIB-152™) and the 
Jurkat 2D10 reporter cell line was previously described [184]. These cells 
lines were cultured with Roswell Park Memorial Institute (RPMI) medium 
in presence of 10% FBS and gentamicin (10 μg/ml).  
 
Mouse embryonic fibroblasts (MEFs) from HIV-1 transgene Tg26 mice 
were obtained from 17-day-gestation embryos after mechanical 
dissociation [190]. MEFs were cultured in DMEM with 10% FBS. 
 
3.3 Co-Transfection of TZM-bl with pX260-LTR-Cas9 and pCMV-Tat 
2.5 x 105 TZM-bl cells were plated in a 6 well tissues culture plate. At 24 
hours, the cells were transfected with 0.5 μg of pX260-LTR plus 0.5 μg of 
pCMV (pcDNA3.1) for control cells and 0.5 μg of pX260LTR + 0.5 μg  
pCMV-Tat plasmid for Tat treated cells using the lipofectamine 2000 
transfection reagent (Invitrogen, USA); un-transfected cells were used as 
negative control. A total of 1 μg of DNA was added in 50 μl of opti-MEM 
medium. 50 μl of opti-MEM was mixed with 5 μl of lipofectamine in a 
second eppendorf and incubated for 5’ at RT, after which the diluted DNA 
was added to the lipofectamine 2000 mixture (1:1 ratio) and incubated for 
20’. During this incubation, cellular growth medium was replaced with 750 
μl of opti-MEM per well and 150 μl of the reaction mixwas added 
dropwise onto the cells. At 4 hours, the transfection mixture was removed 
from cells and fresh 10% FBS DMEM was added. Cells were harvested 
at 2 days post-transfection to analyze the ability of Tat to activate LTR 
promoter by western blot. 
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3.4 Lentiviral Packaging  
2.5x106 HEK 293 cells were plated in a 100mm dish and transduced to 
package Cas9 or gRNAs A/B into lentiviral vectors using the calcium 
orthophosphates (CaPO4) precipitation method. Briefly, DNA is mixed 
with calcium chloride in a phosphate solution, resulting in the formation of 
a calcium-phosphate-DNA precipitate. This precipitate was then added 
onto HEK293 cells. pMDLg/pRRE (Addgene 12251), pRSV-Rev 
(Addgene 12253) and pCMV-VSV-G vectors (Addgene 8454) were used 
for the packaging of pKLV-U6-LTR A/B-PGKpuro2ABFP, while Lenti-
LTR− 80/+ 66-Cas9-Blast, psPAX2 (Addgene 12260) and pCMV-VSV-G 
(Addgene 8454) vectors were used for Cas9 packaging. At 24 and 48 
hours, the supernatants were collected and centrifuged at 3000 RPM for 
10 minutes and filtered using 0.45 μm filter to remove cellular debris. 
Lentiviruses were then concentrated by ultracentrifugation (2h, 25000 
RPMI, with 20% sucrose cushion) and the pellets were resuspended 
overnight (O/N) in Hanks Balanced Salt Solution (HBSS) (Lonza, USA). 
Viral titer was determined after resuspension.  
 
3.5 Viral Titer 
1x106 HEK 293 cells were plated in a 24-well plate and transduced at 24 
hours with five serial dilutions of viral stock (25 μl of lentivirus stock was 
diluted in 250 μl of serum free medium in the presence of 8 μg of 
polybrene).  At 24 hours, growth medium was replaced with fresh 10% 
FBS DMEM and at 1 day the cells were treated with TSA/PMA (250 
nM/16 nM) to induce LTR promoter and Cas9 expression. Cas9 Flag was 
detected with an immunohistochemistry assay while the lentiviruses 
harboring the gRNAs were quantified with microscopy using blue 
fluorescent protein as the marker. 
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3.6 Immunocitochemistry for Cas9   
HEK 293 cells were fixed with 4% paraformaldehyde in PBS for 10 
minutes at RT, washed with 250 μl of PBS and permeabilized with 0.25% 
Triton 100X in PBS. The primary antibody, mouse anti Flag, was diluted 
at 1:200 in PBS containing 0.05% Triton 100X and 1% BSA and was 
incubated for 2 hours at 37° C. After incubation, the cells were washed 3 
times in PBS containing 0.05% Triton 100X for 5 minutes and incubated 
with the secondary antibody, anti mouse FITC conjugated diluted 1:200 
in PBS with 0.05% Triton 100X and 1% BSA for 2h at 37C. Later, cells 
were washed 3 times for 5 minutes each in PBS containing 0.05% Triton 
100X and were imaged using fluorescent microscopy. 
 
3.7 TZM-bI Transduction with pLENTI-LTR-Cas9  
1X106 TZM-bl cells were plated in a 12-well plate for 24 hours prior to 
adenoviral vector transduction.  4 wells were transduced with human 
adenovirus type 5 (De1/e3) Ad-GFP (catalog # SL100708, Signa Gen 
Laboratories, MD) at an MOI of 15, 4 wells were transduced with Ad-GFP 
at an MOI of 12, 4 wells were transduced with Ad-CMVTat at an MOI of 
3, and 4 wells were transduced with Ad-Tat at an MOI of 15. Adenoviral 
stocks were diluted in opti-MEM medium and 500 μl of mixture was 
added per well. Fresh 10% FBS DMEM was added to the cells after 1h of 
incubation. 24 hours later the cells were treated with lentiviral particles 
containing SaCas9, gRNAs A/B or empty vector to test the ability of 
spCas9 to induce gene editing on LTR promoter of TZMb-1 cells in 
presence of gRNAs and different amounts of Tat. pLENTI-LTR-Cas9 
containing LTR -80/+66 (MOI1), pKLV-gRNA-empty (MOI 8,6,4 and 0) 
and pKLV-gRNA LTR A and B (MOI 0/0, 1/1, 2/2 and 4/4) were used for 
the three different MOIs of Tat.  The proper amount of virus was 
transferred to a new eppendorf tube containing opti-MEM (500 μl final 
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volume) and polybrene (8 μg/ml) and 500 μl of viral mix was added in 
each well. Normal 10% FBS DMEM and 1% penicllin/streptomycin was 
added after 24 hours. Cells were harvested at 48 and 96 hours and 
processed for PCR, Western Blot, and Luciferase assays.  
 
 
 
Table 3: Transduction Conditions for TZM-bl Cells with Adenoviral Vectors 
 
Table 4: Transduction Conditions for TZM-bl Cells with Lentiviral Vectors 
 
3.8 Stable Cell Lines  
1x105 TZM-bl cells per well were plated in a six-well tissue culture dish 
and transfected with 1 μg of pX260-LTR (−80/+66)-Cas9 using 
Lipofectamine 2000 reagent (Invitrogen, USA) to induce puromycin 
resistance. At 24 h cells were transferred into a 100-mm dish and treated 
with 1μg/ml puromycin (Sigma, USA) for the selection of Cas9 
expressing clones. After two weeks, the clones were visualized in an 
inverted phase contrast microscope and the selection of the positive 
clones was performed using cloning cylinders (Corning, MA). Briefly after, 
cells were washed, and the bottom of the cloning cylinder was dipped 
into a sterile silicone grease creating an isolated well around the colony 
 Adeno null/GFP Adeno Tat Cell 
number 
 3x106 IU/μl 3x106 IU/ul  
1 MOI 15 - 106 /12 well 
2 MOI 12 MOI 3 106 /12 well 
3 - MOI 15 106 /12 well 
  Lenti pKLV-
gRNA-
empty 
Lenti 
pKLV-
LTRA 
Lenti 
pKLV-
LTRB 
Lenti LTR-
Cas9 
Cell 
number 
 3x104 IU/μl 1.4x106 
IU/μl 
1.8x106 
IU/μl 
1.3x103IU/μl  
1 MOI 8  - - 1/4 2x106 
2 MOI 6  MOI 1  MOI 1 1/4 2x106 
3 MOI 4  MOI 2  MOI 2 1/4 2x106 
4 - MOI 4  MOI 4 1/4 2x106 
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of interest. Then, the clones were treated with 200 μl of 0.25 % trypsin for 
3 minutes at 37˚C and transferred into a 6-well dish.  
 
The TZM-bl Cas9 stable cell line was transduced with pKLV-gRNA-empty 
(MOIs of 8,6,4 and 0) and pKLV-gRNA LTR A and B (MOIs of 0/0, 1/1, 
2/2 and 4/4) as previously described. At 24 hours, cells were infected 
with HIV-1JRFL or HIV-1SF162 and harvested at 48 and 96 hours post-
infection for PCR, western blot and luciferase analysis. 
 
3 μg of pX260-LTR (−80/+66)-Cas9 was used to electroporate 5x105 
Jurkat 2D10 cells to create a Cas9 stable line. Electroporation was 
completed using a Neon System machine (Invitrogen, USA) with the 3 
applications of voltage for 10 ms at 1350 V. Cells were plated in a 6-well 
dish and new medium containing 0.5 μg/ml of puromycin was added at 
48 hours.  The following week, cells were diluted to 10 cells/ml and 50 μl 
of the dilution was plated in 96 well plate for 2 weeks in presence of 10 % 
FBS RPMI medium.  
Jurkat 2D10 pX260-LTR (−80/+66)-Cas9 stable cell line was transfected 
with pKLV-gRNA-empty and pKLV-gRNA LTR A/B alone or together with 
pCMV-empty (pcDNA3.1) and pCMV-Tat plasmids. PCR, qPCR, western 
blot and flow cytometry assays were performed after 48h.  
 
3.9 Infection of TZM-bI with HIV-1JRFL or HIV-1SF162 
1X107 freshly isolated peripheral blood mononuclear cells (PBMCs) were 
activated for 24 hours with Phytohemagglutinins (PHA) (5ug/ml) and 
subsequently infected by spinoculation with 100ng of Gag p24/106 cells 
(total 1μg) for 3 h (2700 RPMI, 32˚C) in Opti-MEM in the presence of 
8μg/ml polybrene. Supernatants of infected PBMCs were collected at 6 
days post-infection and centrifuged at 3000 rpm for 10 minutes and 
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filtered with 0.45 μm filters to prepare HIV-1JRFL and HIV-1SF162 stocks. 
The purified supernatants were lysed with 1 % Triton X-100 (v/v) and viral 
titer was determined using p24 ELISA, following the manufacturer’s 
instructions. 
Stable Cas9/gRNA TZM-bI cells were pre-seeded into a 24-well plate and 
infected by spinoculation for 4 hours with 100ng of Gag p24 per well in 
the presence of polybrene (8μg/ml), after which they were washed three 
times with PBS. The activity of the LTR promoter, which is induced by Tat 
protein, was verified by a luciferase assay using a Modulus II Microplate 
Multimode Reader (Promega, USA).  
 
3.10 Electroporation of 2D10 Cell Line with LTR (-80/+66)-Cas9  
4x106 cells of the 2D10 LTR (-80/+66)-Cas9 stable line were 
electroporated using Neon Transfection system (Invitrogen, CA) with 
pKLV-gRNA LTR A and B (3 μg of each) and the control plasmid, pKLV-
gRNA-empty (6μg), alone or together with varying amounts of pCMV-
Tat86 (0μg, 1μg, 2μg, 6μg). The total DNA used during the transfection 
was normalized to 12 μg for all conditions with the empty pCMV vector 
(pcDNA3.1). This transfection system uses an electronic pipette tip as an 
electronic chamber and has the advantage to improve cellular viability 
and transfection efficiency. 4X106 cells were electroporated 3 times for 10 
ms at 1350V with 12μg of total DNA in 80 μl of buffer T using 10μl tips. 
DNA and whole cell protein extracts were collected after 48 hours of 
electroporation, and 1/10 of the total cells (around 5*105cells) were fixed 
and analyzed for GFP expression. Electroporation conditions per 100 mm 
dish are found in Table 5.  
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Table 5: Electroporation Conditions for the Jurkat 2D10 Stable Cell Line with Lentiviral 
Vectors Expressing gRNAs and a Tat Plasmid 
 
 
3.11 Viral Stocks  
HIV-1NL4-3-EGFP-P2A-Nef plasmid was donated by the School of 
Medicine at the University of Pittsburgh. After transfection of HEK 293T 
cells using CaPO4 precipitation, HIV-1NL4-3-EGFP-P2A-Nef reporter 
virus was obtained by processing the plasmid as a lentiviral stock as 
described before. At 48 hours, viral titer was determined in Jurkat cell line 
using EGFP as marker. HIV-1SF162 and HIV-1JRFL were gifts from Dr. Jay 
Levy, and Dr. Irvin Chen respectively 
 
3.12 Jurkat HIV-1 Infection  
2x106 Jurkat 2D10 cells were transduced with pLENTI-LTR-Cas9 
(−80/+66)-Cas9 (MOI 1), pKLV-gRNA LTR A and B (MOI1/1) and pKLV-
gRNA-empty (MOI2). Briefly cells were spinoculated for 30 minutes (2700 
56 
 
rpm, 32˚C) in Opti-MEM in the presence of 8μg/ml polybrene. At 24 
hours, cells were infected with HIV-1NL4-3-EGFP-P2A-Nef reporter virus 
(MOI 0,01) by spinoculation for 2 hours at 2700 rpm at 32° C in 500 μl 
inoculum containing 8 μg/ml polybrene. Cell pellets were resuspended 
and 500 μl of medium was added after 4 hours. The next day, cells were 
washed in PBS and resuspended in RPMI medium. Flow cytometry, PCR 
and qPCR analysis were performed at 3 and 5 days post-infectiction.  
 
3.13 Cellular Viability Assay 
200 μl of living 2D10 Jurkat cells were quantified for GFP expression 
using Guava EasyCyte Mini flow cytometer (Guava Technologies, 
Germany). Cells were incubated with propidium iodide (10 ug/ml) for 5 
minutes to assess cellular viability. Before GFP quantification in HIV-
1NL4-3-GFP-P2A-Nef infected Jurkat cells, a fixation step in 2% 
paraformaldehyde was performed followed by 3 washes in PBS. 
 
3.14 Luciferase Assay  
After transfection and transduction of TZM-bI cells and the TZM-bI Cas9 
stable cell line with px260-LTR-Cas9 vectors (LTR -456/+66 or -120/+66 
or -80/+66) and LV-gRNAs A/B, whole cell protein extracts were 
analyzed using a Luciferase Reporter Gene Assay kit (Promega, USA). 
Briefly, cell lysates obtained after lysis with Passive Lysis buffer 1X 
(Promega, USA) were centrifuged at 13,000 rpm for 10 minutes at 4˚C 
and supernatants were transferred to a new eppendorf. Luciferase 
activity was assessed by recording luminescence activity with a Modulus 
II Microplate Multimode Reader (Promega, USA). 50 μl of supernatant 
was mixed with 50 μl of freshly made 1X luciferase assay reagent 
substrate. Luminescence activity was corrected for protein concentration. 
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3.15 Western Blot    
Cells were trypsinized and collected and harvested via centrifugation. 
Cell pellets were lysed with 350 μl of Triton X-100-based lysis buffer 
supplemented with 1X nuclear extraction proteinase inhibitor mixture 
(Cayman Chemical, USA) and the lysate was incubated for 30 minutes at 
4°C. Following lysis, cells were centrifuged at 14000 rpm for 10 minutes 
at 4˚C to remove cellular debris. 100 μg of protein was separated by 
SDS-polyacrylamide gel electrophoresis and transferred to nitrocellulose 
membrane (BioRad, USA). Anti-flag M2 monoclonal antibody and mouse 
anti α-tubulin monoclonal antibody were used for the detection of Cas9 
and for loading control. Living Colors® Full-Length GFP Polyclonal 
Antibody rabbit and anti-HIV1 tat antibody were used for the detection of 
GFP and Tat proteins respectively. 
 
3.16 DNA and RNA Isolation  
DNA and total RNA were isolated using the NucleoSpin DNA virus kit 
(Macherey Nagel, Germany) and RNeasy Kit (Qiagen,USA) how 
described in appendix D1-2. DNA and total RNA was subjected to 
qualitative and quantitative analysis through PCR and qPCR analysis.  
 
3.17 HIV-1 DNA Detection and Quantification  
200 ng of DNA was analyzed using Fail Safe PCR kit (Epicentre, USA) 
and Buffer D. Specific PCRs for HIV-1 LTR A/B, 5’UTR, env, LTR gag 
and β-actin (primers listed in table 6) were performed and resolved 
through a 2% agarose gel. After gel purification of the PCR products, the 
DNA sequence was cloned to the TA vector and analyzed by Sanger 
sequencing (Genewiz, USA). 50 ng of DNA and cDNA was quantified 
using Real time polymerase chain reaction (Real Time PCR), performed 
in a LightCycler480 (Roche, Germany). The reaction was based on the 
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use of one Taq man hydrolysis probe specific for HIV-1 5′-UTR, env and 
gag genes and cellular human beta-globin gene as a reference (table 6). 
Simplified protocol was modified from a previously published protocol 
[191]. Genomic DNA of infected HIV-1 U1 cells containing only two 
copies of provirus per diploid genome was used to prepare a standard 
curve. The conditions of the qPCR were the following: 98 °C 5 minutes, 
45 cycles (98 °C 15 s, 62 °C 30 s, 72 °C 1 minute). 
 
3.18 Selection of gRNAs  
The choice of the gRNAs LTR A/B was determined through previously 
obtained results [180, 184] using Jack Lin’s CRISPR/Cas9 gRNA finder 
tool (http:// spot.colorado.edu/∼slin/cas9.html). The same tool was used 
to search for sense and antisense sequences targeting the LTR-Gag 
sequence of HIV-1 genome for saCas9/gRNA target sites containing 20  
bp gRNA targeting sequence plus the PAM sequence (5’NNGRRT3’)  
 
3.19 Transduction of Tg26 MEFs  
1.4x105 cells were plated in a 6-well dish and incubated overnight at 
37˚C. To improve transduction efficiency of transduction, ViraDuctinTM 
AAV Transduction Kit (Cell biolabs, USA) was utilized. Briefly, after 
warming the ViraDuctinTM at RT for 10 minutes, 100 μl of ViraDuctinTM 
AAV Transduction Reagent A (20X) was mixed with 20 μl of AAV 
Transduction Reagent B (100X) and incubated for 5 minutes at RT.  After 
1.88 ml of growth medium was added to the mix and incubated for 5 
minutes, then added to the cells after aspiration of the old cell medium. 
24 hours later the medium was replaced, and the cells were washed 2 
times with complete culture medium. 105 and 106 viral inoculums were 
prepared in 1 ml Opti-Mem, and 500 μl of mix was added to each well 
and incubated at 37˚C, gently shaking every 30 minutes. 1 ml of DMEM 
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was added after 1 hour of incubation. The next day, the inoculum was 
aspirated, and cells were washed with PBS. Cells were harvested 1 week 
later and analyzed for the presence of viral excision by PCR. 
3.20 In vivo rAAV9:saCas9/gRNA administration  
Transgenic mice Tg26 mice carry a transgene derived from the genome 
of HIV-1NL4-3 [192] and rats were used to test the ability of the rAAV9 
saCas9/gRNA construct to perform gene editing in vivo. Experiments on 
animals were performed in our laboratory by Dr. Jennifer Gordon. Briefly 
100 μl of AAV9 (2.73 × 1012) or 100 μl of PBS for control animals was 
injected via the tail vein in 4 transgenic mice at day 0 and day 5. At 5 
days, a blood sample of 2 animals (treated and PBS) was harvested and 
the animals were then sacrificed. The second pair of animals were 
subjected to a second tail vein injection of AAV9 or PBS after 5 days, and 
blood and tissues were collected one week later. The tissues collected 
include the brain, heart, lung, liver, kidney, spleen and peripheral blood. 
A similar approach was used to treat rats (2 female and 2 male) with 2 
injections at 5 days intervals. Tissues were collected after 10 days 
following the 1st injection for DNA and RNA analysis. 
3.21 Analysis of DNA in Animal Models 
For the analysis of DNA from MEFs and from tissues of animal models, 
300 ng of DNA underwent PCR or nested PCR (for tissue samples) using 
the Fail-Safe Kit, buffer D and the primers listed in Table 6. The first step 
of amplification used the following conditions: 94 °C for 5 min, 30 cycles 
(94 °C for 30 s, 55 °C for 30s, 72 C for 30s), 72 °C for 5 min. The PCR 
products were resolved in a 1% agarose gel. 3 μl of the first PCR 
reaction was used to perform nested PCR under the same conditions of 
the first step. DNA obtained from rat samples was subjected to PCR (one 
step) using LTR Fw 1 step and Gag Rev 2 step primers. DNA extracted 
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from tissues of humanized mice underwent other sets of PCRs to detect 
the presence of viral excision from GagD to 3’ LTR and from the 5’-LTR 
to the 3’-LTR of HIV-1 regions using the primers listed in table 6. Nested 
PCR was performed to detect the excision from GagD to 3’LTR using 300 
ng of DNA and Fail-Safe kit, buffer D in 50 μl of reaction processed under 
the following condition: 94 °C for 5 min, 30 cycles (94 °C for 30 s, 57 °C 
for 30s, 72 C for 40s), 72 °C for 5 min. 1μl of the first step of PCR was 
used for the second step following the same protocol. Detection of 
excision from 5’ to 3’LTR 300 ng of DNA was assessed by standard PCR 
conditions, 94 °C for 5 min, 30 cycles (94 °C for 30 s, 55 °C for 30s, 72 C 
for 30s), 72 °C for 5 min. After gel purification of PCR products and 
cloning into the TA vector, the DNA was sent for sequencing (Genewiz, 
USA) and aligned in Clustal Omega software (Cambridgeshire, UK) using 
HIV-1 NL4-3 sequence served as a reference. Human beta globin and 
mouse beta globin PCRs were performed as a loading control (94 °C for 
5 min, 30 cycles at 94 °C for 30 s, 55 °C for 30s, 72 C for 30s, 72 °C for 5 
min). 50 ng of DNA from spleen of humanized mice was subjected to 
absolute quantification (qPCR) for Gag and Pol gene presence as 
previously described. 
 
3.22 RNA Analysis of Rats and Humanized Mice Samples 
RNA isolation was performed on rat and humanized mice tissues using 
Trizol reagent (Ambion, Foster City, CA, USA) and subjected to DNAase 
I treatment. 1μg of RNA was retro-transcribed into cDNA using M-MLV 
reverse transcription (Invitrogen, USA) as described in appendix D3. 
qPCRs specific for gag and env were performed in a LightCycler480 
(Roche, Basel, Switzerland) using 50 ng of rat cDNA and data were 
normalized to the rat beta actin gene (table 6). qPCR reactions were 
61 
 
performed as follows: 98 °C 3 min, 45 cycles (98 °C 15 s, 60 30s, 72 
1min).  
50 ng of humanized cDNA from spleen was used for PCR analysis to 
assess Cas9 and gRNA expression, using beta actin as a loading control. 
 
3.23 Statistical Analysis  
qPCR and luminometric assay results were analyzed as means ± 
standard deviation. p < 0.05 was considered statically significant for 
student T test. 
 
primer sequence 
 Cloning pX260-LTR-
Cas9 constructs 
 
Kpn1-LTR (-454)-S 5’-GGTACCTGGAAGGGCTAATTTGG-3’ 
Kpn1-LTR (-120)-S 5’-GGTACCTCGAGCTTTCTACAAGG-3’ 
Xba1-LTR (-80)-S 5’-TCTAGAGGAGGTGTGGCCTGGGC-3’ 
LTR (+66)-Nco1-AS 5’-CCATGGTAAGCAGTGGGTTCC-3’ 
Cloning lentiLTR(-
80/+66)-Cas9-Blast 
construct 
 
Nhe1-LTR(-80)-S 5’-GCTAGCGGAGGTGTGGCCTGGGC-3’ 
LTR(+66)-Xba1-AS 5’-TCTAGATAAGCAGTGGGTTCC-3’ 
 Cloning 
px601SaCa9LTR1GagD 
construct 
 
LTR1 T708 F 
5’-CACCGCAGAACTACACACCAGGGCC-3’ 
LTR1 T709 R 
5’-AAACGGCCCTGGTGTGTAGTTCTGC-3’ 
Gag D 760 F 
5’-CACCGGATAGATGTAAAAGACACCA-3’ 
Gag D 761 R 5’-AAACTGGTGTCTTTTACATCTATCC-3’ 
 LTR PCRs  
LTR -417/S 2step 5’-GATCTGTGGATCTACCACACACA-3’ 
LTR -19/AS 2step 5’-GCTGCTTATATGTAGCATCTGAG-3’ 
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LTR -374/S 1 step 5’-TTAGCAGAACTACACACCAGGGCC-3’ 
LTR +43/AS 1 step 5’-CCGAGAGCTCCCAGGCTCAGATCT-3’ 
b- actin Fw 5’-CTACAATGAGCTGCGTGTGGC-3’ 
b-actin Rev 5’-CAGGTCCAGACGCAGGATGGC-3’ 
5’UTR fw 5’GTTCGGGCGCCACTGCTAGA3’ 
5UTR rev 5’TTAAGCCTCAAAGCTTGCC3’ 
 Taqman qPCRs  
HIV-1 Gag Fw 5’-AAGTAGTGTGTGCCCGTCTG-3’ 
HIV-1 Gag Rev 5’-TCGAGAGATCTCCTCTGGCT-3’ 
HIV-1 Gag Probe 5’-FAM-CTGTTCGGGCGCCACTGCTA-ZEN- 
IowaBlackFQ-3’ 
Hs b-globin Fw 5’-CCCTTGGACCCAGAGGTTCT-3’ 
Hs b-globin Rev 5’-CGAGCACTTTCTTGCCATGA-3’ 
Hs b-globin probe: 5’-FAM-GCGAGCATCTGTCCACTCCTGATGCTGTTA 
TGGGCGCTCGC-ZEN-IowaBlackFQ-3’ 
Hs b-actin F 5’-TGGACTTCGAGCAAGAGATG-3’ 
Hs b-actin R 5’-GAAGGAAGGCTGGAAGAGTG-3’ 
Hs b-actin probe: 5’-FAM-CGGCTGCTTCCAGCTCCTCC-ZEN- 
IowaBlackFQ-3’ 
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primer sequence 
 LTR1 GagD PCR  
LTR fw 1 step 5’-AATTGCGGCCGCTGGAAGGGCTAATTTGGTCCC-3’ 
Gag rev 1 step 5’-TGTCACTTCCCCTTGGTTCTCTC-3’ 
LTR fw 2 step 5’-AAAAGAATTCGTGGATCTACCACACACAAGGC-3’ 
Gag rev 2 step 5'-AAAAGGATCCACCATTTGCCCCTGGAGGTT-3 
Gag-3’LTR PCR  
Gag fw 1 step 5’- GAAAGCGAAAGTAAAGCCAGAGGAGAT-3  
3’LTR rev 1 step 5’-ACACAACAGACGGGCACACACTACTT -3’ 
Gag fw 2 step 5’AAAAGAATTCGACAGCTACAACCATCCCTTCAGACAG-
3’ 
3’LTR rev 2 step 5’-AAAAGGATCCAGCAGTGGGTTCCCTAGTTAGCCAG-
3’ 
5’LTR-3’LTR  
LTR -417 5’-GATCTGTGGATCTACCACACACA-3’ 
LTR -19 5’-GCTGCTTATATGTAGCATCTGAG-3’ 
Reference   
Mouse beta globin fw 5’-CCCTTGGACCCAGCGGTACT-3’ 
Mouse beta globin rev 5’-GTTATCACCTTCTTGCCATG-3’ 
Hs b-actin F 5’-TGGACTTCGAGCAAGAGATG-3’ 
Hs b-actin R 5’-GAAGGAAGGCTGGAAGAGTG-3’ 
 Taqman qPCRs  
HIV-1 pol/int F 5’-TCCAGCAGAGACAGGGCAAG-3’ 
HIV-1 pol/int R 5’-TGCCAAATTCCTGCTTGATCCC-3’ 
HIV-1 pol/int probe 5’-HEX-CGCCCACCAACAGGCGGCCTTAACTG-ZEN-
IowaBlackFQ-3’ 
HIV-1 Env F 5’- TCCTTGGGATGTTGATGATCT-3’ 
HIV-1 Env R 5’- TGGCCCAAACATTATGTACC-3’ 
HIV-1 Env probe 5’-FAM-TGGTGGTTGCTTCTTTCCACACA-ZEN-
IowaBlackFQ-3’ 
Beta actin rat fw 5’ AGCGCAAGTACTCTGTGTGG3’ 
Beta actin rat rev 5’ AACAGTCCGCCTAGAAGCAT 3’ 
Beta actin rat probe 5’-FAM-CCTCCATGGTGCACCGCAA -ZEN-IowaBlackFQ-
3’ 
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Table 6: Primer Sequences for PCR and qPCR Assays 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RT-PCRs 
 
 
LTR 1 fw 5’-GCAGAACTACACACCAGGGCC-3’ 
Gag D fw  5’-GGATAGATGTAAAAGACACCA-3’ 
pX601gRNAscaffold/R 5’-CGCCAACAAGTTGACGAGAT-3’ 
SaCas9/263/F 5’-TCGACTACAACCTGCTGACC-3’ 
SaCas9/SEQ1 5’-GGTGGGCTTCTTCTGCTT-3’ 
b- actin fw 5’-CTACAATGAGCTGCGTGTGGC-3’ 
b- actin rev 5’-CAGGTCCAGACGCAGGATGGC-3’ 
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4. Results 
4.1 Determination of the minimal promoter region activated by Tat 
To test the ability of Tat to activate different regions of the LTR promoter, 
TZM-bl cells were co-transfected with pCMVTat or pCMV and px260 
LTRCas9 (-456/+66, or 120/+66 or (-80/+66). At 48 hours, cells were 
harvested and processed for DNA and total protein extraction. Western blot 
analysis showed that Tat induces Cas9 expression (160KDa) in all three 
LTR constructs tested. A low level of Cas9 expression is detected in the 
absence of pCMVTat, suggesting a basal activation of LTR promoter by 
cellular transcriptional factors. Tubulin serves as the loading control 
(Figure14).  
                     
Figure 14: Determination of the minimal promoter region activated by Tat. Western 
blot was performed on TZM-bI protein lysates co-transfected with pCMVTat/ pCMV and 
three different px260 constructs harboring three regions spanning the HIV-1LTR Promoter (-
456/+66)/ (-120/+66) or (-80/+66) for the detection of Cas9FLAG (160 KDa), α-tubulin 
(55kDa) and Tat (14 kDa). Lane 1-2: transfection with px260LTR -456/+66, lanes 3-4: 
transfection with px260LTR -120/+66, lanes 5-6: transfection with px260LTR -80/+66. 
(Figure reproduced with permission from Kaminski R. et al., 2016 and a Creative Commons 
CC-BY license) [185]. 
After showing the ability of Tat to activate the minimal promoter LTR -
80/+66, further studies were designed to evaluate the efficiency of delivery 
of LTR (-80/+66) spCas9 system in TZM-bI and Jurkat 2D10 cells using a 
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lentiviral delivery system. After this result, we evaluated the ability of Tat to 
activate integrated copies of spCas9 gene and induce the excision of viral 
DNA in HIV-1 infected TZM-bI LTRSaCas9 stable cell line and in latently 
infected Jurkat 2D10 LTRSaCas9 stable cell line. At the end we analyze 
the capacity of spCas9 system in Jurkat cells to induce gene editing in the 
early stage of HIV-1 infection investigating the possibility to produce a 
vaccine able to prevent HIV-1 reinfection.  
 
Studies in vivo were also performed to test the efficiency of AAV9 delivery 
and gene editing strategy in animal models using a shorter version of 
Cas9, saCas9.  
 
4.2 Increase of Cas9 expression in the presence of Tat 
After developing a lentiviral vector carrying SpCas9 gene under the control 
of LTR (-80/+66) promoter, TZM-bI cells were transduced with adGFP MOI 
15 and adTat MOI 3 and 15. At 24 hours, cells were treated with a lentiviral 
vector containing SpCas9, gRNAs A/B or empty vector to test lentiviral 
delivery of spCas9 to cells and to induce gene editing. Analysis by western 
blot at 48 hours assessed the production of Cas9 after transduction. 
Results showed increased production of Cas9 in the presence of Tat (lane 
5-12) and a homogenous level of tubulin expression (figure 15). These 
results suggest that Tat transduction induces Cas9 expression in the model 
system.  
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Figure 15: Cas9 expression is activated by Tat. Western Blot of TZM-bI protein lysates 
transduced with adGFP MOI 15 and adTat MOI 3 and 15 and treated with pKLV-gRNA-
empty (MOI 8,6,4 and 0) and pKLV-gRNA LTR A and B (MOI 0/0, 1/1, 2/2 and 4/4) and lenti 
LTRCas9. Lane 1-4:  transduction with adGFP MOI 15, lanes 5-8: transduction with adGFP 
MOI 12 and adTat MOI 3, lanes 9-12: transduction with adTat MOI 15. Α-tubulin was used 
like loading control. Cas9 production is activated by Tat (lanes 5-12). (Figure reproduced 
with permission from Kaminski R. et al., 2016 and Creative Commons CC-BY license) [185]. 
. 
4.3 Viral excision increases in presence of Tat and gRNAs 
DNA was extracted from the same cells at 48 and 96h, and analyzed with 
PCR specific for the LTR region. PCR products of 395 base pairs and 205 
base pairs, corresponding to the full length LTR and the truncated LTR, 
were detected in presence of Tat and gRNAs A/B (lane 6-8, 10-12) at 48 
and 96h, likewise in the absence of Tat at 96h (lane 4). The truncated LTR 
product, indicating viral promoter excision, is not visible in the negative 
control (absence of gRNAs, lane 1/5/9), (figure 16). The sequence of 
truncated LTR promoter was analyzed in BLAST using the HIV-1 NL4-3 
sequence as reference. Results revealed the presence of editing of a190 
bp region in the LTR promoter region.  Full length and truncated LTR 
sequences of one sample (lane 6) are shown in figure 17. 
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Figure 16: Increased viral excision in presence of Tat and gRNAs. TZM-bI Cells were 
transduced adGFP MOI 15 and adTat MOI 3 and 15 and treated with pKLV-gRNA-empty 
(MOI 8,6,4 and 0) and pKLV-gRNA LTR A and B (MOI 0/0, 1/1, 2/2 and 4/4) and lenti 
LTRCas9. PCR analysis was performed at 48 H (top) and 96 H (bottom). Lane 1-4:  
transduction with adGFP MOI 15, lanes 5-8: transduction with adGFP MOI 12 and adTat 
MOI 3, lanes 9-12: transduction with adTat MOI 15. (Figure reproduced from Kaminski R. et 
al., 2016 and Creative Commons CC-BY license) [185]. 
 
 
 
Figure 17: DNA analysis of truncated LTR confirms viral excision: After gel purification 
of PCR on TZM-bI cells transduced with adGFP MOI 15 and adTat MOI 3 and 15 and 
treated with pKLV-gRNA-empty (MOI 8,6,4 and 0) and pKLV-gRNA LTR A and B (MOI 0/0, 
1/1, 2/2 and 4/4) and lenti LTRCas9 the DNA was cloned in TA and sent for sequencing. 
Sequences were aligned to the refence LTR region of the HIV-1NL4-3 sequence. Sequences 
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of gRNA A and B are Highlighted in Green, Primers in Blue, and the PAM Sequence in Red. 
(Figure reproduced from Kaminski R. et al., 2016 and Creative Commons CC-BY license) 
[185]. 
4.4 Decreased LTR promoter activity in presence of Tat 
LTR promoter excision was assessed through a luciferase assay of 
transduced TZM-bl cells. At 48 and 96 hours, supernatants of the 
transduced cells were collected and processed to determine luciferase 
activity. As shown in figure 18a (48h) and 18b (96h), the transcriptional 
activity of the LTR promoter decreased in the presence of Tat and gRNAs 
A/B. A basal activity of the LTR promoter is observed in the presence of 
adGFP MOI 15, which likewise decreased in the presence of gRNAs. Cells 
treated with increasing concentrations of gRNAs showed the higher level of 
viral DNA excision after 48h of incubation. These results corroborate with 
data obtained from PCR assays. 
 
 
 
 
 
 
 
 
 
 
 
A 
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Figure 18 A/B: Decrease of LTR promoter activity in presence of Tat. Luciferase Assays on 
TZM-bI cells transduced with adGFP MOI 15 and adTat MOI 3 and 15 and treated with 
pKLV-gRNA-empty (MOI 8,6,4 and 0) and pKLV-gRNA LTR A and B (MOI 0/0, 1/1, 2/2 and 
4/4) and lenti LTRCas9 at 48 Hours (18A) and 96 Hours (18B) post-Lentiviral transduction. 
(Figure reproduced from Kaminski R. et al., 2016 and Creative Commons CC-BY license) 
[185]. 
4.5 Cas9 expression is activated during HIV-1 infection  
To investigate the efficacy of excision of viral DNA during the early stages 
of HIV-1 infection, new experiments were conducted on TZM-bI pX260-
LTR (−80/+66)-Cas9 stable line. 24 hours after transduction with different 
MOIs of LV-gRNAs A/B (MOI 0/0, 1/1, 2/2 and 4/4) and pKLV-gRNA-empty 
(MOI 8,6,4 and 0), the cells were infected with HIV-1JRFL or HIV-1SF162.  
Analysis of WB showed activation of Cas9 protein in presence of Tat 
produced during HIV-infection.  Equal amounts of the house keeping gene 
α-tubulin were detected (Figure 19). 
                     
B 
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Figure 19: Cas9 expression during HIV-1 infection. Western Blot was performed on protein 
lysates from the pX260-LTR (−80/+66)-Cas9 Stable Cell Line transduced with pKLV-gRNA-
empty (MOI 8,6,4 and 0) and pKLV-gRNA LTR A and B (MOI 0/0, 1/1, 2/2 and 4/4) and 
Infected with HIV-1JRFL or HIV-1SF162. (Figure reproduced from Kaminski R. et al., 2016 and 
Creative Commons CC-BY license) [185]. 
 
4.6 Tat protein expression drives viral excision.    
PCR assay analyzed the presence of viral editing after Tat-mediated Cas9 
activation. A truncated LTR fragment (205 bp) was detected in the 
presence of HIV-1JRFL infection with gRNAs A/B (lane 6-8, figure 20).  The 
different results obtained between the two HIV-1 viral strains may be the 
result of a differential ability of these viruses to infect TZM-bI cells. A higher 
level of infectivity by HIV-1SF162 virus may explain the higher level of Cas9 
protein detected in western blot (figure 19). However, it must be noted that 
a high production of viral DNA may reduce the final total amount of edited 
product which is not easily detected by PCR.  
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Figure 20:  Tat protein production drives viral excision: PCR Analysis of the pX260-LTR 
(−80/+66)-Cas9 Stable Cell Line Transduced with pKLV-gRNA-empty (MOI 8,6,4 and 0) and 
pKLV-gRNA LTR A and B (MOI 0/0, 1/1, 2/2 and 4/4) and Subsequently Infected with HIV-
1JRFL or HIV-1SF162. Lanes 1-4 unifected cells, lanes 5-8 cells infected with HIV-1 JRFL, 
lanes 9-12 cells infected with HIV-1 SF162. LTR full length is detected at 395 bp, truncated 
LTR at 205 bp. (Figure reproduced from Kaminski R. et al., 2016 and Creative Commons 
CC-BY license) [185]. 
 
4.7 Decreased LTR promoter activity during HIV-1 infection  
At 48 hours post-infection, cells were harvested and processed for analysis 
with a luciferase assay to assess the ability of Cas9 to interfere with the 
transcriptional activity of the LTR promoter in the TZM-bI pX260-LTR 
(−80/+66)-Cas9 stable line. Luciferase activity decreased in the presence 
of both HIV-1 strains, and was directly correlated to the amounts of gRNAs 
used (higher decrease for MOI 4/4, figure 21).  
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Figure 21: Decreased LTR promoter activity in presence of Tat Detection of the 
transcriptional activity of the pX260-LTR (−80/+66)-Cas9 stable cell line transduced with 
pKLV-gRNA-empty (MOI 8,6,4 and 0) and pKLV-gRNA LTR A and B (MOI 0/0, 1/1, 2/2 and 
4/4) and subsequently infected with HIV-1JRFL or HIV-1SF162.  On the left side unifected cells, 
in the middle HIV-1 JR-FL infected cells, on the left side HIV-1 SF162 infected cells. (Figure 
reproduced from Kaminski R. et al., 2016 and Creative Commons CC-BY license) [185]. 
4.8 Cas9 expression in Jurkat 2D10 cells as model of latently infected 
cells 
Next, the ability of our system to excise the virus from latently infected cells 
was assessed. A similar experiment to the previously described 
experiments was conducted using Jurkat 2D10 cells; a cell line that 
harbors integrated copies of HIV-1 NL4-3, whose genome lacks a portion 
of the Gag and Pol genes, as well as possessing the reporter green 
fluorescent protein (GFP) replacing the Nef gene. The 2D10 cells were 
transduced with lenti-SpCas9 LTR -80/+66 plasmid to generate a stable 
cell line with integrated copies of LTR -80/+66-Cas9 gene. The 2D10 stable 
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cell line was transduced with pKLV (6 μg) or pKLV -gRNAs A/B (3 μg of 
each) and with pCMV or pCMV-Tat plasmid (0 μg, 1 μg, 2 μg, 6 μg). 
Western blot analysis at 48 hours revealed an increased level of Cas9 and 
GFP expression in the presence of Tat. The level of GFP protein 
decreased in presence of higher concentration of gRNAs A/B and Tat, 
suggesting that HIV transcription was decreased.  The basal level of Cas9 
expression may be attribute to the low constitutive level of Tat expression 
in 2D10 cells line (figure 22). 
 
Figure 22: Cas9 expression in Jurkat 2D10 cells. Western Blot analysis for the detection 
of Cas9, GFP and Tat in the Jurkat 2D10-LTR (−80/+66)-Cas9 stable cell line transduced 
with pKLV-gRNA-empty (6 μg) and pKLV-gRNA LTR A and B (3 μg of each) in presence of 
pCMV-Tat86 (0,1,2,6 ug) and pcDNA3.1.  α-tubulin was used like loading control. Lanes 1-4 
cells transduced with pKLV-gRNA-empty, lanes 5-8 cells transduced with and pKLV-gRNA 
LTR A and B. (Figure reproduced from Kaminski R. et al., 2016 and Creative Commons CC-
BY license) [185]. 
4.9 Viral excision in the Jurkat 2D10 cell model of latently infected 
cells 
Specific PCR for the detection of the LTR promoter showed the presence 
of a truncated LTR region (227 base pairs) in presence of gRNAs and Tat  
(Figure 23 lanes 5-8). Analysis of the truncated LTR sequences confirmed 
the excision of 190 bp fragment between gRNA A and B in LTR promoter 
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(Figure 24). Excision efficiency was determined as a percentage of the 
ratios between truncated versus full length LTR and quantified by qPCR 
assay. Results were expressed in percentage of cut efficiency of treated 
cells versus untreated (figure 25). 
 
Figure 23: Viral excision in a model of HIV-latent infection. PCR Assay of the Jurkat 
2D10-LTR (−80/+66)-Cas9 stable cell line transduced with pKLV-gRNA-empty (6 ug) and 
pKLV-gRNA LTR A and B (3ug for each) in presence of pCMV-Tat86 (0,1,2,6 ug) and 
pcDNA3.1. Lanes 1-4 cells transduced with pKLV-gRNA-empty, lanes 5-8 cells transduced 
with and pKLV-gRNA LTR A and B. Percent of viral excision is showed on the bottom after 
qPCR quantification of LTR region. (Figure reproduced from Kaminski R. et al., 2016 and 
Creative Commons CC-BY license) [185]. 
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Figure 24: Sequence analysis of the truncated LTR Fragment. Sanger sequencing was 
performed to analyse the sequence of LTR truncated fragment after PCR in the Jurkat 
2D10-LTR (−80/+66)-Cas9 stable cell line following transduction with pKLV-gRNA LTR A 
and B (3ug for each) in the presence of Tat (6ug). (Figure reproduced from Kaminski R. et 
al., 2016 and Creative Commons CC-BY license) [185]. 
 
Figure 25:  Excision Percentage of the LTR Promoter region.  qPCR was performed in 
Jurkat 2D10-LTR (−80/+66)-Cas9 Stable Cell Line transduced with pKLV-gRNA-empty (6 
μg) and pKLV-gRNA LTR A and B (3 μg for each) in presence of pCMV-Tat86 (0,1,2,6 ug) 
and pcDNA3.1. Data are represented as arbitrary units (AU). (Figure reproduced from 
Kaminski R. et al., 2016 and Creative Commons CC-BY license) [185]. 
 
4.10 GFP reduction in Jurkat 2D10 cells as model of latently infected 
cells 
To investigate the ability of Tat to activate the LTR promoter, flow 
cytometry analysis was performed to quantify the number of GFP, an index 
of viral reactivation. An increased percentage of GFP cells was detected in 
the presence of Tat and in absence of gRNAs. The percentage of viral 
reactivation drastically decreases when gRNAs are expressed and Cas9 is 
induced by Tat (figure 26) 
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Figure 26:  Decrease of viral reactivation. Analysis of flow cytometry was performed on 
Jurkat 2D10-LTR (−80/+66)-Cas9 stable cell line transduced with pKLV-gRNA-empty and 
pKLV-gRNA LTR A and B (3 μg of each) in presence of pCMV-Tat86 (0,1,2,6 ug) and 
pcDNA3.1 to detect GFP expression.  (Figure reproduced from Kaminski R. et al., 2016 and 
Creative Commons CC-BY license) [185]. 
 
4.11 Viral excision in Jurkat cells during the early stage of infection 
To evaluate the possibility of vaccine generation based on a gene editing 
strategy, further studies were performed on Jurkat cells to evaluate the 
presence of Cas9 in the cells as protection from HIV-1 reinfection. Jurkat 
cells were transduced with pLENTI-LTR-Cas9 (−80/+66) Cas9 (MOI 1), 
pKLV-gRNA (MOI1/1) or pKLV negative control (MOI2). At 24 hours cells 
were infected with HIV-1 NL4-3 EGFP-P2APNef.  
 
PCR analysis was performed at 3 and 5 days post-infection, revealing the 
presence of a truncated LTR fragment (205 bp) whose intensity is higher at 
day 5, possibly due to increased production of Tat and subsequent Cas9 
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activation (figure 27). Indel mutations were detected by analysis of 10 
clones (trunc LTR 1-10) of the truncated LTR fragment amplified at day 5 
(clones 2/6/8/10, figure 28). 
 
 
 
 
 
 
 
Figure 27:  Viral excision in Jurkat Cells at the early stage of infection. Jurkat cells 
were transduced with pLENTI-LTR-Cas9 (−80/+66) Cas9 (MOI 1) and pKLV-gRNA 
(MOI1/1) or pKLV Negative Control (MOI2) and infected with HIV-1 NL4-3 EGFP-P2APNef 
(MOI 0.01). Analysis PCR was performed at 3 and 5 days post infection for the detection of 
LTR region. (Figure reproduced from Kaminski R. et al., 2016 and Creative Commons CC-
BY license) [185]. 
 
 
 
 
 
Figure 28:  Sequence Analysis of Truncated LTR Fragments. Jurkat cells were 
transduced with pLENTI-LTR-Cas9 (−80/+66) Cas9 (MOI 1) and pKLV-gRNA (MOI1/1) or 
pKLV negative control (MOI2) and infected with HIV-1 NL4-3 EGFP-P2APNef (MOI 0.01). 
After PCR analysis the truncated LTR fragment was gel purified, cloned in TA vector and 
sent for Sanger sequencing. Sequence of HIV-1NL4-3 was used as reference. Yellow 
highlights the presence of indel mutations. (Figure reproduced from Kaminski R. et al., 2016 
and Creative Commons CC-BY license) [185]. 
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To investigate if gene editing occurs between the 5’LTR and 3’LTR, PCRs 
specific for genes positioned in the middle of HIV-1 sequence, 5’UTR (+97 
to +235) and env (+5828 to +5977)) were performed at 3 and 5 days post-
infection. PCRs showed the presence of 139 and 150 bp fragments, 
respectively, whose intensities decreased at day 5 compared to day 3. 
Amplification of the housekeeping gene beta actin (270 bp) was used as a 
loading control (figure 29). 
 
 
 
 
 
 
 
 
Figure 29:  Excision of the viral DNA between LTR regions. PCR Assay was performed 
on Jurkat Cells transduced with pLENTI-LTR-Cas9 (−80/+66) Cas9 (MOI 1) and pKLV-
gRNA (MOI1/1) or pKLV Negative Control (MOI2) and infected with HIV-1 NL4-3 EGFP-
P2APNef (MOI 0.01) at 3 and 5 days after infection for the detection of viral DNA region 
between LTR regions. Beta actin DNA was used as quality control. (Figure reproduced from 
Kaminski R. et al., 2016 and Creative Commons CC-BY license) [185]. 
4.12 GFP reduction in Jurkat cells on the early stage of infection 
To investigate the ability of Cas9 to protect cells from HIV-1 reinfection, the 
level of GFP positive cells was calculated as marker of viral expression. A 
decrease of positive cells was observed at day 3 (-64%), 5 (-84%) and 8 (-
88%) post infection, revealing the ability of Cas9 to suppress viral 
expression at early stages of infection (Figure 30).  
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Figure 30: GFP reduction in Jurkat cells on the early stage of infection. Flow cytometry 
assay detection of GFP positive Jurkat Cells transduced with pLENTI-LTR-Cas9 (−80/+66) 
Cas9 (MOI 1) and pKLV-gRNA (MOI1/1) or pKLV Negative Control (MOI2) and infected with 
HIV-1 NL4-3 EGFP-P2APNef (MOI 0.01) at day 3, 5 and 7 post infection. (Figure 
reproduced from Kaminski R. et al., 2016 and Creative Commons CC-BY license) [185]. 
 
4.13 Reduction of GPF protein levels in presence of gRNAs and Cas9 
in Jurkat cells 
The presence of gRNAs and LTR Cas9 was assessed using fluorescence 
microscopy with BFP as a marker. The presence of gRNAs and lentiviral 
vector encompassing Cas9 and gRNAs was visually detected (figure 31 
top). Analysis of GFP showed decreased positive cells in the presence of 
Cas9 and gRNAs compared to gRNAs only (figure 31 middle). Qualitative 
and quantitative analysis was performed using light microscopy, showing 
no cytopathic effects and a comparable number of cells. Cells treated with 
LTR-Cas9/gRNAs appeared healthy and possessed no morphological 
changes, suggesting a lack of cytotoxicity by gene editing (figure 31 bottom 
and figure 32). 
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Figure 31: Reduction of GPF protein levels in presence of gRNAs and Cas9. 
Fluorescent and phase microscopy analysis of Jurkat Cells transduced with pLENTI-LTR 
(−80/+66)-Cas9 and pKLV-gRNA LTR A and B or pKLV-gRNA LTR A and B only and 
infected with HIV-1 NL4-3 EGFP-P2APNef. On the bottom gRNAs and Cas9 expression 
using BFP as marker, on the middle GFP levels in presence of gRNAs only and gRNAs plus 
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Cas9. In the bottom morphological view of the cells. (Figure reproduced from Kaminski R. et 
al., 2016 and Creative Commons CC-BY license) [185]. 
 
 
Figure 32: Quantification of Viable Jurkat Cells. Quantification was performed on Jurkat 
cells after transduction with pLENTI-LTR-Cas9 (−80/+66) Cas9 (MOI 1) and pKLV-gRNA 
(MOI1/1) or pKLV Negative Control (MOI2) and infected with HIV-1 NL4-3 EGFP-P2APNef 
(MOI 0.01). (Figure reproduced from Kaminski R. et al., 2016 and Creative Commons CC-
BY license) [185]. 
 
4.14 Gag DNA and RNA reduction in Cas9 treated Jurkat cells at the 
early stage on infection 
Analyses by qPCR was performed on DNA and RNA extracted from Jurkat 
cells transduced with pLENTI-LTR-Cas9 (−80/+66) Cas9 (MOI 1), pKLV-
gRNA (MOI1/1) or pKLV negative control (MOI2) and infected with HIV-1. 
Results showed a decrease of Gag gene at days 3 and 5 in treated cells 
compared to control (figure 33 left side).  Analysis of Gag RNA was 
performed after reverse transcription of RNA into cDNA, with a 91 and 96% 
decrease detected at 3 and 5 days post-infection, respectively, in treated 
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cells (figure 33 right side). These results reveal a potential use of gene 
editing to protect cells from HIV-1 reinfection.  
 
 
Figure 33:  Cas9 DNA and RNA reduction in Jurkat cells. Quantification of Gag copies 
on DNA and cDNA of Jurkat Cells transduced with pLENTI-LTR (−80/+66)-Cas9 and pKLV-
gRNA LTR A and B or negative control (pKLV empty) and Infected with HIV-1 NL4-3 EGFP-
P2APNef (MOI 0,01) at 3 and 5 days post infection. (Figure reproduced from Kaminski R. et 
al., 2016 and Creative Commons CC-BY license) [185]. 
 
4.15 Viral Excision in MEF cells treated with rAAV9 SaCas9/gRNAs 
Following in vitro studies, a construct was created to allow the delivery of 
the Cas9 system in vivo using an innovative AAV9 delivery system. AAV9 
requires the use of a smaller Cas9, saCas9, which is 1kb shorter than 
spCas9. The gRNAs LTR1 and GagD were introduced in the same 
construct of SaCas9 under the control of two separate U6 promoters. 
To test the functionality of this new system studies in vitro were performed 
on MEFs cells, obtained from Tg26 mice. At one-week post-transduction 
with rAAV9 SaCas9/gRNAs, cells were harvested and subjected to PCR 
analysis.  
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Specific PCR was performed to amplify the LTR Gag region of HIV-1 
genome, obtaining a full-length fragment of 1323 bp and a truncated 
fragment of 345 bp, not detected in untreated cells (figure 34).  
 
 
Figure 34: Viral excision on DNA of MEF cells. Mouse embryo ﬁbroblasts (MEFs) were 
prepared from 17-day-gestation embryos by mechanical and enzymatic dissociation. PCR 
analysis of MEF cells after transduction with rAAV9 SaCas9/gRNAs. Cells were harvested 
after one week and DNA extraction was performed for viral excision detection. Lane 1 
untrasduced cells, lane 2 and 3 transduced cells (MOI 105 and 106).  Full lenght LTR-Gag 
region is detected at 1323 bp, truncated LTR region is detected at 345 bp. (Figure 
reproduced from Kaminski R. et al., 2016 and Nature Publishing group) [186]. 
 
4.16 Viral excision in vivo in Tg26 mice treated with rAAV9 
SaCas9/gRNAs 
After verifying the functionality of the AAV9 SaCa9LTR1/GagD construct in 
vitro, studies in vivo were performed on Tg26 mice to evaluate the 
efficiency of delivery and gene editing in animal model tissues. 4 animals 
were treated with AAV9 virus or PBS (2 mice received one injection while 
the other two received two injections). Nested-PCRs were performed on 
blood and tissues including liver, heart, spleen, lung, kidney and brain.  
One full length fragment was detected in treated and non-treated animals 
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(1171 bp), while a truncated fragment (160 bp), an index of viral excision, 
was detected only in treated animals after one and two AAV9 injections 
(figure 35). Analysis of the truncated LTR1GagD fragment confirmed the 
excision of 1011 base pair fragment (figure 36). 
 
Figure 35: Viral excision in vivo in tissues of Tg26 mice. Nested PCR was performed on 
DNA of tissues of Tg26 mice treated with rAAV9saCas9/gRNAs to detect viral excision. 
Lane 1: tissue from mouse treated with 100 μl of PBS as negative control, lane 2: tissue 
from raav9saCas9/gRNAs (2.73×1012) treated mouse, lane 3: MEF with 
rAAV9saCas9/gRNAs treatment (MOI 106). (Figure reproduced from Kaminski R. et al., 
2016 and Nature Publishing group) [186]. 
 
Figure 36: Sequence analysis of truncated fragments from liver DNA. The truncated 
LTR-GAG fragment detected after PCR on DNA of liver tissue was gel purified, cloned in TA 
vector and sequenced. The Position of the Primers and the gRNAs are highlighet in the 
figure in blue and green respectively. (Figure reproduced from Kaminski R. et al., 2016 and 
Nature Publishing group) [186]. 
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4.17 Viral excision in vivo in Tg26 rats treated with rAAV9 
SaCas9/gRNAs  
The same set of experiments was then performed on 4 rats (2 treated, 2 
untreated). PCR data obtained from blood showed the presence of a 
truncated LTR1GagD fragment (221 bp) in the treated animals but not in 
control samples (figure 37). The sequence of the truncated fragments 
obtained in blood PCR was analyzed with BLAST using HIV-1 NL4-3 as 
reference sequence, which showed the excision of a 955 bp fragment 
(figure 38).  
 
Total RNA was extracted by blood samples, converted into cDNA and 
analyzed by qPCR to check the presence of Gag and Env transcripts. 
Results showed a decrease of transcript production for both regions in 
treated animals compared to controls, suggesting a loss of function of the 
LTR promoter in treated animals (figure 39, left and right side). Data were 
normalized by the number of rat cells using beta actin as reference. Similar 
results were obtained from RNA prepared from lymph nodes (data not 
shown). 
 
Figure 37: Viral excision in DNA of bloof of rats treated with rAAV9SaCa9 gRNAa. 
Retro-orbital inoculation of rAAV9: Cas9/gRNA or 100 μl of PBS was injected into 4 mice. 
PCR was performed on blood DNA of rats with (lanes 2 and 4) and without (lanes 1 and 3) 
SaCas9 treatment to detect viral excion. (Figure reproduced from Kaminski R. et al., 2016 
and Nature Publishing group) [186]. 
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Figure 38: Sequence analysis of a 221 bp truncation fragment. After PCR on DNA blood 
samples, the truncated fragment was gel purified, cloned in TA vector and sent for 
sequencing. 4 clones were analyzed for the truncated fragment obtained by PCR on DNA 
blood of the female treated rats and 4 clones for the male treated rats. Primers are shown in 
gray, gRNAs sequence in green, and the PAM sequence in red. (Figure reproduced from 
Kaminski R. et al., 2016 and Nature Publishing group) [186]. 
 
 
Figure 39: Percent of viral RNA decrease in the blood of treated Tg26 rats. qPCR was 
performed on blood RNA of male and female rats treated with and without rAVV9SaCas9, 
for the detection of Gag and Env transcripts. (Figure reproduced from Kaminski R. et al., 
2016 and Nature Publishing group) [186]. 
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4.18 Viral excision in vivo in humanized mice treated with rAAV9 
SaCas9/gRNAs  
Nod/Cg-Prkdcscid II2rgtm1wjI/SzJ (NSG) mice were used to test the ability of 
the AAV9SaCas9LTR1GagD construct to induce gene editing in a 
humanized animal model. After the injection of human peripheral blood 
lymphocytes (PBLs) into the mice, they were infected with HIV-1NL4-3 and 
then were divided in three groups, 5 mice received no antiretroviral 
treatment and one injection of AAV9 construct and 13 were treated with 
LASER ART therapy. The 13 mice were then divided into a non-treatment 
group (4 mice) and a Cas9-treated group (9 mice). Tissues were harvested 
after 5 weeks of CRISPR treatment. Specific PCRs were performed to 
amplify 5’ LTR GagD, GagD 3’LTR and 5’LTR-3’LTR regions of HIV-1 
genome (figure 40) on spleen, GALT, kidney, lung, liver and brain tissue to 
investigate the ability of CRISPR/Cas9 to induce double stranded breaks in 
the viral DNA as illustrated in figure 40. Excision between 5’LTR and GagD 
results in the editing of 798 bp fragment and the generation of a 
truncated/end joined fragment of 193 bp. Excision between GagD and 
3’LTR results in the editing of 8.097 bp fragment and the generation of a 
truncated/end joined fragment of 523 bp. Excision between 5’LTR and 
3’LTR consists in the editing of 9.074 bp fragment and the generation of a 
truncated/end joined fragment of 396 bp. 
 
Figure 40: HIV-1 genome map. Illustration of gRNAs positions and the size of truncated 
amplicons expected after editing of viral DNA in LTRs and GagD regions by CRISPR/Cas9. 
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Excision between 5’LTR and GagD consists in the editing of 798 bp fragment and the 
generation of a truncated/end joined fragment of 193 bp. Excision between GagD and 
3’LTR consists in the editing of 8.097 bp fragment and the generation of a truncated/end 
joined fragment of 523 bp. Excision between 5’LTR and 3’LTR consists in the editing of 
9.074 bp fragment and the generation of a truncated/end joined fragment of 396 bp.  
PCRs performed on tissues of spleen, GALT and kidney of mice AAV9-
CRISPR/Cas9 treated and LASER ART/AAV9 CRISPR/Cas9 treated 
detected the presence of amplicons of 193 and 523 bps resulting from 
excision between the 5’LTR and GagD and GagD and the 3’LTR. A 
fragment of 396 bp derived from both full length or truncated LTRs after the 
excision between the 5’ LTR and the 3’ LTR was detected by specific PCR 
(Figure 41).  
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Figure 41: Viral excision in spleen, GALT, and kidney of humanized mice HIV-1 
infected. PCRs of Spleen, GALT, and Kidney tissues from CRISPR/Cas9 treated 
Humanized Mice CRISPR/Cas9 (n:5), LASER+CRISPR/Cas9 Treated (n:9) and only 
LASER-ART Treated (n:4). Tissues were harvested after 5 weeks from CRISPR treatment 
and analysis of DNA was performed for the detection of viral excision between 5’LTR and 
GagD, GagD and 3’LTR, 5’LTR and 3’LTR regions. One asterisk denotes that the 
highlighted fragment is Cas9 correlated and verified by sequence analysis. Two Asterisks 
indicate aspecific fragments not Cas9 related. 
PCR performed on tissues of lung, liver and brain of mice AAV9-
CRISPR/Cas9 treated and LASER ART/AAV9 CRISPR/Cas9 treated 
detected the presence of amplicons of 193 and 523 bps resulting from 
excision between the 5’LTR and GagD and GagD and the 3’LTR. (Figure 
42). 
 
Figure 42: Viral excision in lung, liver and brain of humanized mice HIV-1 infected. 
PCRs of Spleen, GALT, and Kidney Tissues from CRISPR/Cas9 Treated Humanized Mice 
CRISPR/Cas9 (n:5), LASER+CRISPR/Cas9 Treated (n:9) and only LASER-ART Treated 
(n:4). Tissues were harvested after 5 weeks from CRISPR treatment and analysis of DNA 
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was performed for the detection of viral excision between 5’LTR and GagD, GagD and 
3’LTR. One asterisk denotes that the highlighted fragment is Cas9 correlated and verified by 
sequence analysis. Two Asterisks indicate aspecific fragments not Cas9 related. 
The specificity of each truncated/end-joined fragment revealed in these 
PCRs was gel purified, cloned in TA vector and analyzed using Sanger 
sequencing that revealed the presence of indel mutations, deletions and 
insertion, which was CRISPR Cas9 related. In figure 43 sequences 
obtained from the analysis of the truncated/end joined viral DNA resulting 
from the excision between 5’LTR/GagD and GagD/3’LTR of spleen, GALT 
and kidney tissues showed the presence of indel mutations, deletions and 
insertion CRISPR/Cas9 related. 
 
 
92 
 
Figure 43: Analysis of truncated/endjoined viral DNA sequence. The truncated/end 
joined LTR-GAG viral DNA detected after nested PCR for the DNA of each tissue was gel 
purified, cloned in TA and sent for sequence. In the figure is reported representative DNA 
sequences obtained from the analisys of DNA from spleen, GALT and Kidney tissues. Pam 
Sequences are in red, gRNA sequences are in green, and the presence of indel mutations 
is denoted by arrows 
PCR specific for the housekeeping gene human and mouse beta actin was 
performed on tissues as loading control and control of DNA quality. Figure 
44 showed beta actin amplification on spleen, GALT and kidney.  
 
 
Figure 44: Quality control on spleen, GALT and kidney DNA of humanized mice HIV-1 
infected. PCR on human and mouse β-actin gene was performed as quality control of the 
DNA used to verify viral excision. Mice CRISPR/Cas9 (n:5), LASER+CRISPR/Cas9 Treated 
(n:9) and only LASER-ART Treated (n:4).  
Specific human beta globin and mouse beta globin PCRs were performed 
on DNA to show the co-presence of human and mice cells in spleen tissue 
(Figure 45). The presence of human cells was detected in all mice 
samples, showing the ability of the injected PBLs to reach different tissues 
in this animal model. 
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Figure 45: Detection of human beta globin in spleen tissue of humanized mice HIV-1 
infected. PCR on human beta globin was performed on spleen DNA as marker of presence 
of human cells on tissues of humanized mice. Mouse β-Globin PCR was performed as 
loading control. Mice CRISPR/Cas9 (n:5), LASER+CRISPR/Cas9 Treated (n:9) and only 
LASER-ART Treated (n:4).  
4.19 Cas9 and gRNAs expression in the tissues Humanized mice  
Total RNA was extracted by spleen tissues of mice AAV9-CRISPR/Cas9 
treated, LASER ART/AAV9 CRISPR/Cas9 treated or only LASER ART 
treated, converted in cDNA and analyzed for the expression of saCas9, 
LTR1 and GagD gRNAs, human beta actin was used as quality control 
(Figure 46). The expression of Cas9 and gRNAs was detected in AAV9-
CRISPR/Cas9 treated and LASER ART/AAV9 CRISPR/Cas9 treated mice 
but no in LASER ART group, who was treated with antiretroviral drugs but 
without CRISPR/Cas9. The lack of gRNAs expression for some mice in 
AAV9-CRISPR/Cas9 treated and LASER ART/AAV9 CRISPR/Cas9 
treated groups may depends from the long time within the injection of the 
AAV construct carrying the gRNAs and the time of harvest of the tissues.  
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Figure 46: Cas9 and gRNAs expression in spleen tissue of humanized mice HIV-1 
infected. PCR was performed on spleen cDNA to detect the expression of Cas9 (on the 
top) and gRNA (middle row). Human and mouce β-actin was used as the loading control 
(bottom). Mice CRISPR/Cas9 (n:5), LASER+CRISPR/Cas9 Treated (n:9) and only LASER-
ART Treated (n:4).  
4.20 No viral DNA was observed in two LASER ART/AAV9 
CRISPR/Cas9 treated mice   
DNA from spleen of AAV9-CRISPR/Cas9 treated, LASER ART/AAV9 
CRISPR/Cas9 treated and only LASER ART treated mice was used for 
qPCR assay for the quantification of pol and env region to assay the 
integrity of viral genome. Absence of viral DNA was observed in 2 mice, 
M#4346 and M#4349, suggesting the presence of viral sterilization (Figure 
47) that was also confirmed with RNase scope analysis and ultrasensitive 
digital droplet PCR performed from collaborators at the University of 
Nebraska Medical Center (data not shown). 
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Figure 47: Decreased pol and env copies on DNA spleen tissue of humanized mice 
HIV-1 infected. qPCR on pol and env viral DNA was performed for experimental Mouse 
Groups, Note the Absence of Viral DNA Highlighted by Arrows for Mouse #4346 and Mouse 
#4349 in LASER ART group. 
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5. Discussion 
Human immunodeficiency virus is a member of the Retroviridae family that 
was first detected in France at the Pasteur institute. In 1981, HIV was 
recognized as causative agent of acquired immune deficiency syndrome 
[193]. Retroviruses are spherical enveloped viruses characterized by a 
specific mechanism of replication in which the viral RNA is converted into 
DNA and integrates in the host genome. HIV-1 belongs to the genus of 
Lentivirus encompassing the human immunodeficiency virus 1 and 2. The 
epidemic spread of HIV-1 initiated with zoonotic infection of SIV in the 
1900s. HIV-2, transmitted by sooty mangabeys, is diffused in Africa and 
causes a similar disease to HIV-1 but is less transmissible [4]. HIV-1 
contains 4 different groups, characterized by different sources of 
transmission. The main group derives from chimpanzees and is 
responsible for the worldwide HIV-1 pandemic.  Since 1982, 76.1 million 
people in the world have become infected with HIV-1 and 35 million people 
have died of HIV-1 related illnesses. Currently 36.5 million people live with 
HIV infection while the number of deaths has decreased after the 
introduction of ART therapy. HIV-1 transmission occurs by sexual, 
percutaneous, and peritoneal routes, with a 15- 25% risk of transmission 
during pregnancy and 35-40% risk during the breastfeeding period [13].  
 
HIV-1 infection is characterized by an initial infection of CD4+ T cells in the 
mucosal tissues, followed by an eclipse phase which is characterized by 
asymptomatic or associated with minor symptoms where the virus spreads 
throughout the lymphoid system. After this phase the viral load decreases 
until reaching a set point due to CD8+ T cell action. This period is not 
associated with clinical manifestations and can persist up to 15 years. The 
last stage of HIV-1 is characterized by the point at which the level of CD4 
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positive cells reaches 100 cells per μl of blood. This stage presents with an 
increased incidence of opportunistic infections and HIV-1 related diseases.  
 
The HIV-1 genome consists of two copies of linear single stranded positive 
sense RNA [2] and is characterized by the presence of non-coding regions 
involved in the regulation of the gene expression and by regions 
expressing regulatory, accessory, structural and enzymatic proteins.  
 
The target cells of HIV-1 infection are memory and naïve T lymphocytes, 
macrophages and dendritic cells. Viral replication can be divided in two 
phases, early and late stages. During the early stage, the virus binds the 
host cell receptors and integrates its genome in the human DNA. In the late 
stage, after the expression of viral proteins, the new viral particles are 
released outside the infected cells to facilitate the infection of new cells. 
The regulation of viral replication is controlled by HIV-1 proteins, primarily 
Nef, Rev and Tat that are produced during the early stages of infection and 
are involved in the downregulation of cellular receptors and in the control of 
HIV-1 protein expression. Rev regulates the trafficking of the viral 
transcripts to the cytoplasm and Tat interacts with the TAR region of the 
viral genome inducing the activation of pTEF and the phosphorylation of 
RNA pol II resulting in an increased elongation of viral transcripts. The 
importance of these proteins explains the interest of the scientific 
community to use molecules able to target the pathways regulated by Tat 
and Rev [194]. Hamy discovered a new compound, stilbene CGA137053 
that binds to Tat and interferes with the viral expression [195]. 
Balachandran identified three molecules which reduce the levels of both 
proteins altering the transcripts levels and HIV-1 protein expression [196].  
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In 1990, the therapy of antiretroviral drugs was discovered, with these 
molecules targeting different steps of HIV-1 replication to suppress the viral 
load in treated patients. However, ART is ineffective against latent viral 
reservoirs, including memory T cells, monocytes, naïve T cells and 
macrophages [93] or anatomic sanctuaries such as CNS and GALT [97], 
that become a source of viral reactivation after ART interruption. The 
limitations of ART to eradicate HIV-1 virus as well as the high cost make 
the development of an alternative strategy to completely eradicate the virus 
necessary.  
 
Different vaccine trials had been tested in the past to control the spread of 
the epidemic, but only one, the RV144 trial, showed a reduction in HIV-1 
acquisition. The difficultly to create an efficient vaccine is due to the 
genomic diversity of different HIV-1 strains and the high frequencies of 
mutations that occur during viral infection. Recently, the shock and kill 
therapy provides the use of molecules to induce viral reactivation and lysis 
of the infected cells combined with antiretroviral drugs that after viral 
reactivation avoid the spread of new infection. This system is associated 
with cell toxicity and a low ability to induce viral reactivation. Other 
strategies involved the use of antibodies against the binding site of CD4 
with env viral protein and against the CD3 receptor to induce HIV-1 
resistance in infected T cells that are recognized and lysed by CD8 positive 
cells [197]. 
 
Recently, the use of gene editing platforms has been largely assessed for 
the development of an HIV-1 cure. Different approaches involve small 
interfering RNAs, meganucleases, ZFNs, TALENs and the CRISPR/Cas9 
system. The first example of gene editing targeting HIV-1 DNA was 
performed with a recombinase of bacteriophages to target Tat and LTR 
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regions [111]. The application of homing endonucleases for genome 
editing was limited due the large size of these proteins and the low 
specificity, instead ZFNs and TALENs molecules were successfully 
employed to target HIV-1 infected cells. After the initiate case of the Berlin 
patient, other HIV-1 patients with Hodgkin’s lymphoma received 
transplantation of CCR5 wild type hematopoietic stem cells, resulting in 
reduction of the viral load, but eventually showed viral rebound. This 
resulted in the development of new strategies, characterized by the 
treatment of autologous hematopoietic cells with gene editing molecules 
targeting CCR5, CXCR4 cellular receptor or viral genes, such as the LTR 
promoter, and the infusion of the modified cells into patients. A second 
strategy consists of the direct administration of the gene editing molecules 
to the patients. Different studies were developed, employing ZFNs 
targeting the CCR5 receptor to treat autologous T cells [121], [122]. ZFNs 
showed positive results in animal models where the use of CD4 positive 
cells T cells against CCR5 induced HIV-1 resistance. This resistance 
persisted after engraftment of these T cells in NOD-SCID IL2rγc null (NSG) 
mice [124]. A clinical trial using CCR5 ZFNs (SB-728) to test the specificity 
of this system in HIV-1 infected patients was performed [198]. TALEN 
molecules were also employed to target the CCR5 receptor, HIV Tat or HIV 
LTR region [131], [132], [135]. The limitations of TALENs are the high cost 
of production, the large size and less specificity comparing to the new 
strategy of CRISPR/Cas9. Gene editing induces breaks in the DNA strands 
disrupting opening reading frame or introducing indels mutations or 
insertions of specific sequences, allowing the utilization of this technique 
for the treatment of different disease such as cystic fibrosis, sickle-cell 
anemia, or Duchenne’s muscular dystrophy, diabetes, heart disease, 
schizophrenia, autism, transthyretin-related hereditary amyloidosis and 
dominant-negative forms of retinitis pigmentosum [138]. Different studies 
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were performed in T cells using CRISPR/Cas9 system to induce viral 
excision targeting different viral regions or cellular receptors, such as the 
TAR region [171], the CXCR4 coreceptor [172], [173], the CCR5 
coreceptor [181] [176] and the LTR, Pol and Rev regions [177]. The 
importance to target the U3 region in the LTR promoter, which is the NF-Κb 
binding site, was recognized by multiple groups [178], [179], [180], [184]. 
Hu et al showed the importance of using a multiplex system of gRNAs 
delivered by lentiviral vectors to protect the cells from the generation of 
viral escape mutants. In that study, the presence of Cas9 in the cells was 
associated with the acquisition of resistance to new HIV-1 infection. To 
increase the specificity of CRISPR system new Cas9 variants were 
generated. Examples are the creation of a paired nickase, able to induce a 
single break in the two opposite DNA strands increasing the specificity by 
up to 1500-fold [162]. dCas9 was employed to induce transcriptional 
suppression mediated by steric hindrance of Cas9 in the DNA target using 
specific gRNAs that direct Cas9 in the region of interest [163].  
 
Cas9 can be delivered to cells with viral and non-viral delivery systems; 
viral delivery systems include lentiviruses, baculoviruses, AAV viruses 
while no viral delivery systems include cationic polymer polyethleimine, 
liposomes, lipis nanoparticles, virus-like particles, bacteriophages, and 
nanoparticles [170]. AAVs are low immunogenic viruses which allow the 
transduction of dividing and non-diving cells and can be efficiently 
delivered in a large variety of human tissues. Lentiviral vectors are used to 
transduce dividing and non-dividing cells but their capacity for packaging 
allows the introduction of larger inserts than AAV vectors. The use of 
nanoparticles is a promising strategy that already has important results in 
animal models. A significant reduction of viral RNA was detected in the 
plasma of HIV-1 infected immunodeficient NOD-scid IL-2rγ-/- mice that were 
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engrafted with PBMCs treated with nanoparticles containing molecules 
targeting the CCR5 receptor compared to the negative control [199]. 
Different experiments in animal models were performed by Yin et al., using 
AAV system to deliver saCas9 and a combination of gRNAs, 2 specific for 
the LTR region, one for Gag and one for Pol in HIV-1 transgenic mice, 
ecoHIV acutely infected mice, and humanized bone marrow, liver, thymus 
(BLT) mice harboring chronic viral infection, obtaining viral excision in 
different tissues of all three animal models [188].  
 
The efficiency of CRISPR/Cas9 in vivo is still a topic that requires more 
investigation, primarily to optimize the delivery in all tissues, particularly the 
brain. Additionally, more studies using humanized mice or monkeys are 
necessary to identify a delivery system able to induce the excision of the 
viral DNA from all infected cells without toxicity. The presence of a 
regulated system to be specifically activated by the virus may be an 
important key in animal models to induce gene editing in an early stage of 
infection before development of viral latency and without off target effects.  
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6. Conclusion  
Following the initiation of ART therapy in HIV-1 patients, the viral load 
decreases within two weeks from the beginning of the treatment, resulting 
in the reduction of free virus and the death of infected macrophages and 
partially activated T cells, whose half-life is longer than fully activated T 
cells. Latently infected resting CD4+ T cells represent a source of viral 
reactivation when ART therapy is discontinued [200]. One study by the 
Visconti group focused on 14 HIV-1 infected patients who discontinued 
ART. Viral rebound was observed in these patients, even in those who 
started ART therapy early, suggesting that the existence of a viral reservoir 
is more important to viral reactivation than the number of latently infected 
cells [201]. Recently a child from Mississippi, born from a HIV-1 mother 
who was not ART treated, underwent antiretroviral treatment for 18 months 
after her birth, resulting in an undetectable viral load at 23 months, 
suggesting that early ART initiation serves to reduce the pool of infected 
cells and can eliminate free viral particles [202]. Currently only 53% of 
people diagnosed with HIV-1 undergo ART treatment. Statistical analysis 
reveals that only a long term pharmaceutic intervention (more than 73 
years) may completely eradicate the virus from each latently infected cell, 
suggesting that this approach works as a functional cure, serving to control 
the viral load, as opposed to functioning as a sterilizing cure [203].  
 
Tat protein has a critical role in the transcriptional regulation of viral genes 
by binding the TAR region located downstream of the initiation site of 
transcription of the RNA, resulting in the recruitment of the pre-initiation 
and initiation complexes to the transcription start site allowing the 
transcriptional elongation of the RNA [60]. The interaction of Tat with other 
transcriptional factors such as NF-Kb, p300/CBP and GCN5 [90], [203], 
[204] may influence viral and cellular transcription. The role of Tat in the 
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regulation of HIV-1 replication resulted in the interest of the scientific 
community to develop drugs such as inhibitors of the interaction Tat-Tar to 
interfere the spreading of infection [194], [195]. Different approaches were 
used to target viral or cellular genes involved in viral replication, using gene 
editing strategies. In 2014, ZFNs were used in a clinical trial to target 
CCR5 receptor in 12 patients after the interruption of ART, which showed 
slow viral rebound, whose spread was correlated to the degree of gene 
editing obtained in both alleles [122]. Recently, the CRISPR/Cas9 system 
appears to be a promising approach for the cure of HIV-1 by targeting 
cellular receptors, such as CCR5 or CXCR4 [176], [206] or viral genes 
[171], [177], [178]. Hu et al [180] used lentiviral vectors to target HIV-1 
LTRs regions obtaining the excision of the integrated provirus in latently 
infected cells such as microglia, TZM-bI reporter and U1 cell lines. These 
data corroborate with results obtained by Kaminski targeting the same U3 
LTR region in human T lymphocytic cell line 2D10, PBMCs and CD4 
positive cells obtained from HIV-1 infected patients [184]. 
 
In our first study, published in Scientific Reports, we used lentiviral vectors 
in vitro to target HIV LTRs using the same gRNAs sequence of a previous 
study published from our laboratory [180], [184] with an innovative Tat-
inducible Cas9 system, generating a negative feedback loop in the 
presence of HIV. During the early stages of infection, Tat regulates viral 
replication (positive feedback) and simultaneously induces the activation of 
Cas9 promoter (shown by western blot), which excises the LTR promoter 
from TZM-bI cells and Jurkat 2D10 cells in the presence of specific gRNAs 
resulting in reduced transcriptional activity (shown by luciferase assay) and 
in a reduced GFP production respectively. Viral excision was reported after 
two days of infection of Jurkat cells previously treated with Cas9, 
suggesting a pre-exposure prophylactic action. Similar experiments were 
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performed on human primary astrocytes and microglia, obtaining a 
reduction of viral expression (data no shown). This inducible system avoids 
a long term Cas9 expression that may result in off target effects into the 
genome of human cells, but father investigations must be performed to test 
the functionality and the specificity of this system in vivo.  
 
The second experiment we performed, published in Gene Therapy, was 
the first proof of HIV-1 excision in vivo by using a Cas9 system delivered 
by the AAV9 vector. In this study, we targeted two different regions of HIV-
1, LTR and Gag, obtaining viral excision in different tissues of Tg26 mice 
and rats. The advantage of AAV vectors is the reduced toxicity and 
immune response by the host immune system and the high delivery 
efficiency of these viral vectors in different tissues. Similar results were 
obtained in a recent study performed by Yin and colleagues targeting 
different regions of HIV-1 genome using AAV vectors in HIV-1 transgenic 
mice, Eco HIV acutely infected mice, and BLT mice [188].  
 
The last set of experiments was performed on HIV-1 infected humanized 
mice. Results showed complete HIV eradication and absence of viral 
rebound in 29% of the infected animals that were previously subjected to 
ART treatment. Deep sequencing analysis revealed the absence of 
CRISPR/Cas9 related off-target effects. This study documented for the first 
time the presence of viral sterilization in vivo, but more studies must be 
performed to evaluate the functionality of CRISPR/Cas9 system in SIV-
infected monkey models. This new approach, combined with antiretroviral 
therapy, represents a promising strategy for HIV-1 sterilization and a 
prospect towards clinical trials. 
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APPENDIX A: MOLECULAR CLONING 
 
A1: PCR Products 
 
Three different regions of LTR promoter were amplified (figure 48, LTR -
120/+66, -80/+66 and -38/+66 regions) using pNL4-3 DNA virus as the 
template and the primers listed in table 6 containing the restriction sites for 
KpnI and XbaI. PCRs were performed under the following conditions: 
 
COMPONENT VOLUME/REACTION 
Fail Safe PCR Enzyme Mix (1.25 
Units) 
0.5 μl 
10 μM primer F 1ul 
10 μM primer R 1ul 
Buffer D 2X 25 ul 
template 300 ng 
DNAsi-free water To 50 ul 
 
Table 7: PCR conditions for the LTR promoter amplification 
 
The cycling conditions of the assay were as follows: 
94° C for 3 minutes, 25 cycles (94° C for 30 s, 55° C for 30 s, 72° C for 
30s) and 72° C for 7 minutes. 
 
 
 
Figure 48: Illustration of the LTR HIV-1 promoter. LTR promoter and portions of LTR 
promoter for the cloning into the px260 plasmid to test the ability of Tat to activate the 
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minimal promoter region. (Figure modified from Kaminski et al., 2016, [185], under 
permission from a Creative Commons CC-BY license] 
 
 
A2. Gel Purification of PCR products 
Gel purification was performed with QIAquick Gel Extraction kit (Qiagen, 
Germany) using columns that bind DNA in presence of high concentrations 
of salt, allowing the elimination of all impurities and the elution of pure 
DNA. Briefly, DNA was separated on agarose gel. The target fragment was 
cut from the gel and the mass was determined. 5X volume of buffer QG 
was added and the gel was melted at 56˚C for 10 minutes. One volume of 
isopropanol 100% was added to precipitate the DNA and the sample was 
loaded to the provided columns and centrifuged at 13,000 rpm for 60 s. 
The DNA was washed with 750 μl of Buffer PE and centrifuged at 13,000 
rpm for 60s. An additional step of centrifugation was performed for 1 min at 
13,000 rpm to remove any remaining buffer. DNA was eluted in 25 μl of 
DNAase free water and centrifugated at 13,000 rpm for 1min. 
 
A3: Ligation of PCR Products and Transformation 
 
To allow one successful cut of the PCR product with the restriction sites 
created by PCR amplification, the Taq PCR fragments were first directly 
inserted in TA vector (Life Technologies, CA). 
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Figure 49: pCR2.1 Vector Map and Sequence [Invitrogen USA, catalog #K2000-01] 
 
 
The reaction was performed under the following conditions: 
 
COMPONENT VOLUME/REACTION 
ExpressLinkTM T4 DNA Ligase (5U) 1ul 
5X T4 DNA Ligase Reaction Buffer 2ul 
pCR®2.1 vector (25 ng/µL) 2ul 
insert 15ng 
DNAsi-free water To 10 ul 
 
Table 8: Ligation Condition for LTR Cloning into the TA Vector: After gel purification 
LTR producst were cloned in 50ng of TA vector at 16˚C ON. 
 
 
The reaction was incubated at 16˚C O/N and 5μl of ligation product was 
transformed using 50 μl of One Shot® INVF' Chemically Competent E. 
coli (K2000-01, Life Technologies, CA). Samples were incubated on ice for 
30 minutes and then 42°C at 45 seconds (heat shock) and back on ice for 
2 minutes. 500 μl of SOC media was added to allow the growth of bacteria 
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at 37°C. After 1h, 100 μL of suspension was plated on Luria-Bertani (LB) 
agar plates (LB Medium + 2% agar + ampicillin 100 mg/mL for selective 
growth) and incubated at 37°C O/N. At the end, single bacterial colony was 
selected and suspended in LB broth with ampicillin O/N at 37°C for 
miniprep. 
 
 A4:  DNA Isolation from Bacteria  
The extraction of plasmid DNA was carried out using the Qiagen Plasmid 
Minikit (Qiagen, Germany). After O/N incubation the bacterial culture was 
centrifuged at 3000 rpm for 10 minutes and the pellet was resuspended in 
300 μl buffer P1 and 300 μl of lysis buffer P2. After a short incubation of 5’ 
on ice 200 μL of buffer P3 was added to stop the lysis process. The clear 
supernatant, obtained by centrifugation at 14000 rpm for 15 minutes at 
4°C, was mixed with isopropanol (1:1) to precipitate the DNA and 
incubated at -20°C for 1 hour. Samples were then centrifuged at 14000 
rpm for 15 minutes and the pellet was resuspended in 80 μl of DNAase 
free water. The resulting plasmids were sent for sequencing to Genewiz to 
verify the presence of the insert. 
 A5: Digestion of pCR™4-TOPO® TA Vector and pX260-U6-DR-BB-
DR-Cbh-NLS-hSpCas9-NLS-H1-shorttracr-PGK-puro 
After screening the TA vector clones, digestion was performed on the 
clones containing the insert of interest and on the vector pX260-U6-DR-
BB-DR-Cbh-NLS-hSpCas9-NLS-H1-shorttracr-PGK-puro or simply called 
px260 (Addgene #42229, figure 50) harboring the humanized SpCas9 
gene, allowing the creation of a construct where the expression of Cas9 is 
driven by HIV-1 LTR promoter. 
The digestion was performed under the following conditions: 
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(COMPONENT VOLUME/REACTION 
KpnI (10U/ul)/XbaI (20U/ul)* 1ul 
NcoI* 1ul 
Buffer 2.1 10X 5 ul 
vector** 2μg 
DNAsi-free water To 50 ul 
 
*New England Biolab 
**vector: pCR™4-TOPO® TA vector (Life Technologies, CA) or px260-LTR-Cas9 
 
Table 9: Digestion Conditions for LTR Cloning into pX260-U6-DR-BB-DR-Cbh-NLS-
hSpCas9-NLS-H1-shorttracr-PGK-puro. TA vector harbouring the minimal LTR promoter 
and px260-LTR Cas9 were digested with KpnI and XbaI at 37˚C for 3h to allow the creation 
of compatible ends for the ligation step. 
 
 
 
 
 
138 
 
Figure 50: Vector Map of pX260-U6-DR-BB-DR-Cbh-NLS-hSpCas9-NLS-H1-
shorttracr-PGK-puro Plasmid [Addgene #42229]. Restriction Enzymes used for the 
cloning were undelighted in red. 
 
The reaction mixture was incubated at 37°C for 3h and analyzed with a 2% 
agarose gel. Gel DNA purification was performed using QIAquick Gel 
Extraction kit (Qiagen, Germany).  50 ng of digested vector and 100 ng of 
insert were ligated ON at 16˚C in a final volume of 20 μl, usingT4 DNA 
ligase (New England, Biolabs, USA). 
A6: Creation of LENTI-LTR (-80/+66) Cas9-BLAST Construct 
LentiCas9-Blast plasmid (Addgene #52962, figure 51) was digest with NheI 
and XbaI restriction enzymes following the digestion conditions previously 
described. PCR amplification (94 °C 3 minutes, 25 cycles (94 °C 30 s, 55 
°C 30 s, 72 °C 30s) and 72 °C 7 minutes) was performed using primers 
described in table 6 and pNL4-3 as template. The reaction was separated 
with a 2% agarose gel and purified and cloned to the TA vector. Positives 
clones were digested with XbaI and NheI (restriction sites introduced in 
LTR promoter by PCR amplification) and ligated with the digested 
LentiCas9-Blast plasmid. 
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Figure 51: LentiCas9-Blast Plasmid Vector Map [Addgene # 52962]. Restriction 
Enzymes used are circled in red 
 
A7: Creation of px601-CMV/saCas9-LTR1-GagD 
2 μg of px601-AAV-CMV:NLS-saCas9-NLS-3xHA-bGHpA;U6::Bsa1-
SgRNA (Addgene #61591, figure 52) vector was digested with 1μl of BsaI 
in 50 μl of reaction mixture for 3h at 37˚C. The digestion mix was purified 
using QIAquick Gel Extraction kit (Qiagen, Germany) and treated with CIP 
under the following conditions: 
 
COMPONENT VOLUME/REACTION 
CIP (10 U/ul) * 1ul 
10X CutSmart® Buffer 5ul 
Digested vector 2ul 
DNAase-free water To 50 ul 
 
*New  England, Biolabs 
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Table 10: De-phosphorylation conditions of px601-AAV-CMV:NLS-saCas9-NLS-
3xHA-bGHpA;U6:Bsa1-SgRNA after Bsa1 digestion. Digested vector was treated with 
CIP enzyme to allow the dephorilation of its extremities at 37˚C for 30 minutes. 
 
The reaction was incubated at 37˚C for 30 minutes and purified using 
QIAquick PCR Purification Kit (Qiagen, Germany) following the 
manufacturer’s instructions.  
Oligonucleotides specific for LTR1 and GagD regions were used to 
generate gRNA sequences. Oligonucleotides were annealed according the 
following method: 
 
• 5μl of oligonucleotides 10 μM (final volume of 10 μl) added in a 1.5 
ml microfuge tube were incubated at 95˚C for 5 minutes 
• the mix was cooled to room temperature after which it was 
phosphorylated and annealed using T4 Polynucleotide Kinase 
(PNK) under the following condition: 
• Reaction was incubated at 37˚C for 30’. 
• 100 nM of reaction mixture was ligated at 14˚C ON with 50 ng of 
p601 SaCas9 LTR1 BsaI linearized 
 
COMPONENT VOLUME/REACTION 
T4 PNK (10U/μl) 0,5 μl 
T4 buffer 10X 2 μl 
Annealed mixture 10 μl 
Deionized water 7.5 μl 
Table 11: Phosphorylation of Annealed Oligonucleotides Mixture 
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COMPONENT VOLUME/REACTION 
Insert* 100 ng 
T4 DNA ligase** 1μl 
T4 DNA Ligase Reaction Buffer 10X 1μl 
Vector BsaI digested*** 50 ng 
DNAese-free water To 10 μl 
      
 *phophotilated oligonucleotides mixture 
  ** New England Biolabs 
***px601 SaCas9 LTR1 BsaI linearized 
Table 12: Ligation Condition for Phosphorylated Oligonucleotides with the px601 
Vector. 
 
5 μl of ligation product was transformed in competent cells and clones were 
screened to check the presence of gRNA. The same protocol was used to 
generate two different px601 constructs containing the sequence of the 
gRNA LTR1 or GagD.  Later 2 μg of px601 SaCas9 LTR1 vector was 
digested with 0.5 μl of EcoRI (20U/μl) and 1 μl of KpnI (10U/μl).  A PCR 
was performed using px601SaCas9GagD construct as template to amplify 
GagD gRNA using the primers T795 and T796 (donated by Dr. Hu). The 
PCR product was treated with infusion kit (Takara Bio, USA) to fuse GagD 
gRNA sequence and the digested px601 SaCas9 LTR1 vector EcoRI/KpnI. 
Reaction conditions are described below: 
Table 13: Infusion treatment conditions to create px601 LTR1 GagD construct. 
Insert and vector were treated with the enzyme premix for 15 minutes at 50˚C and 5μl of 
reaction mix was transformed in the competent cells. 
 
COMPONENT VOLUME/REACTION 
PCR fragment (insert) 50ng 
Linearized vector 100 ng 
5X In-Fusion HD Enzyme Premix 2 μl 
Deionized Water To 10 μl 
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The mix was incubated for 15 minutes at 50˚C, and after that 5μl of 
reaction mixture was transformed using 50 μl of Stellar competent cells, 
sold in In-Fusion HD Plus kits, following the standard protocol of 
transformation. Digestion with BamHI or EcoRI plus NotI was performed for 
the screening of positive clones. 
.  
 
 
 
 
Figure 52: Position of the T795 and T796 primers in px601. These primers were used to 
amplify the gRNA sequence for the cloning of multi-gRNAs in one px601 Vector [Addgene # 
61591]. 
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APPENDIX B: Lentiviral packaging  
 
HEK 293 cells were transfected using CaPO4 precipitation with 15 μg of 
pLENTI LTR− 80/+ 66-Cas9-Blast, 10 μg of psPAX2 containing Gag, Pol, 
Rev and Tat and 6 μg pCMV-VSV-G expressing envelope protein in 450 μl 
of water, supplemented with 50 μl of 2.5M CaCL2. The DNA mixed with 
calcium generates a precipitate that facilitates the entry of DNA into the cell 
by endocytosis. The mixture was added dropwise into 0.5 ml warm HNP 
buffer. The mix was added on the cells, plated on 100 mm dishes in 
presence of 10 ml of growth medium and 50 μM of cloroquine. Fresh 
medium was supplemented after 24h and supernatant was harvested 48 
and 72h later. The same protocol was used to package pKLV-U6-LTR A/B-
PGKpuro2ABFP, using the amounts of DNA founded in the table below.   
Per 100 mm dish see below: 
 
 
pCW-Cas9 psPAX2 pCMV-VSV-G 
Lenti-LTR-
Cas9-blast 
(1,7μg/μl) (2.2 μg/μl) (1.8μg/μl) (2μg/μl) 
1 15 μg 10 μg 6 μg - 
2 - 10 μg 6 μg 15 μg 
 pKLV-gRNA 
empty 
pMDLg/Prre pRSV-Rev pCMV-VSV-G 
(1.28 μg/μl) (2 μg/μl) (2 μg/μl) (1.8 μg/μl) 
1 10μg 8 μg 5 μg/ 3 μg 
   
Table 14: Lentiviral vector packging conditions. HEK 293 cells were transfected with 15 
μg of pLENTI LTR− 80/+ 66-Cas9-Blast, 10 μg of psPAX2 and 6 μg pCMV-VSV-G. The 
same protocol was used to package pKLV-U6-LTR A/B-PGKpuro2ABFP, using 
pMDLg/Prre, pRSV-Rev and PCMV-VSG-G. 
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APPENDIX C: Western Blot 
Western blotting was performed as follows. The cells were washed in PBS, 
harvested and centrifuged at 1200 rpm for 5 minutes. The cell pellet was 
suspended in 350 μl of TNN buffer supplemented with 1X protease inhibitor 
cocktail for mammalian cells (Cayman Chemical, USA). Cellular lysates 
were kept in agitation at 4°C for 30 min and then centrifuged at 14,000 rpm 
at 4°C for 15 minutes. After the preparation of stacking gel (30% 
Acrylamide/0,8% bisacrilamide, 4X Tris Cl/SDS pH 6.8, 10% APS, TEMED, 
distilled water) and running gel 9% (30% Acrylamide/0,8% bis-acrilamide, 
4X Tris Cl/SDS pH 8.8, 10% APS, TEMED, distilled water), 100 µg of 
proteins were mixed with 6 μl of loading dye solution 1x and TNN buffer (40 
μl final volume), denatured at 95°C for 5 min and loaded into the gel. 8 μl of 
protein marker (Colorplus prestained protein marker, Broad range (7-
175kDa), New England Biolabs, USA) was loaded in the first well. After 30 
minutes of run at 100 Volt for 2h in 1X Running Buffer (Tris-Glycine-SDS, 
TGS) (Biorad, USA) the proteins were transferred from the gel to a 
membrane in 1x Transfer Buffer (Tris-Glycine, TG) (Biorad, USA) with 200 
mL of methanol O/N at 4˚C at 60 milliamps. The following day the 
membrane was blocked in 5% non-fat dry milk in PBST (50ml), (0.1% 
Tween 20 in 1X PBS) at RT for 1 hour. The primary antibody was added 
for 3 hours at room temperature, mouse anti-flag M2 monoclonal antibody 
(1:1000, Sigma, USA) and mouse anti-α-tubulin monoclonal antibody 
(1:2000, Sigma, USA), or rabbit anti GFP protein (1:1000, Sigma, USA) 
and rabbit anti-HIV-1-Tat (1:1000, Abcam, USA). The membrane was 
washed 3 times for 5 min with TBST and the secondary antibody solution 
was added at RT for 1 hour, Goat Anti-Mouse IgG FITC conjugated and 
horse anti rabbit rhodamine conjugated, diluted 1:5000 in in 5% No fat dry 
milk in PBST. The membrane was washed 3 times for 5 min with PBST 
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and scanned using an Odyssey Infrared Imaging System (LI-COR 
Biosciences, USA). 
 
 
APPENDIX D: DNA and RNA analysis 
D1: Genomic DNA Extraction from Cells and Tissues 
Nucleospin Tissue Kit (Macherey Nagel, Germany) was used for the DNA 
purification. The procedure was carried out as follows: 25 mg of tissues 
were homogenized in 250 μl of buffer T using a combination of different 
beads following the manufacture’s protocols and the Bullet Blender 
homogenizer (Next Advance, USA) and. The lysate was incubated O/N in 
presence of proteinase K, lysed with 210 μl of B3 lysis buffer at 75˚C for 
15’, precipitated with 210 μl of ethanol and loaded into the column that 
binds specifically the DNA. After centrifugation at 11,000g for 1 minutes, 
the DNA was subject to two steps of wash and at the end, the DNA was 
eluted in 100 μl of DNAase free water. DNA from 107 cells and from blood 
was purified using the manufacturer’s directions.  
 
D2: RNA Isolation from Cells and Blood   
RNeasy Mini Kit (Qiagen, Germany) was used for the RNA extraction 
under the following instructions: 1 x 107 cells were harvested and lysed in 
350 μl of buffer RTL. The lysate was loaded into a QIAshredder spin 
column, centrifuged for 2 min at maximum speed and the eluted product 
was mixed with 350 μl of 70% ethanol and incubated for 1’ at RT. Then the 
mixture was loaded into a RNeasy spin column and centrifuged for 15 
seconds at ≥8000 x g. 350 μl of buffer RW1 was added on the column and 
the samples were centrifuged for 15 seconds at ≥8000 x g. 80 μl of DNase 
solution (10 μl of DNase I stock solution in 70 μl of buffer RDD) was added 
into the membrane and incubated for 15 min at RT.  350 μl of buffer RW1 
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was added on the column and after centrifugation at ≥8000 x g for 15 
seconds, two wash steps were performed with 500 μl of Buffer RPE. 
Samples were centrifuged for 15 s at ≥8000 x g and an additional step of 
centrifugation for 1 minute at full speed was performed to eliminate any 
residual buffer. RNA was eluted in 40 μl of RNase-free after centrifugation 
for 1 min at ≥8000 x g. 
 
D3: Retrotranscription  
RNA was retrotranscribed using M-MLV reverse transcription enzyme 
(Invitrogen, USA). Briefly 1 μg of total RNA was mixed with 1μl of oligo dT 
(500 ug/ml), 1 μl of 10 mM dNTP mix (10 mM of each nucleotide) and 
distilled water in a final volume of 12 μl. The mix was incubated at 65°C for 
5 minutes and then on ice. 4μl of 5X first strand buffer, 2 μl of 0.1M DTT 
and 1μl of RNase OUT recombinant ribonuclease inhibitor (40U/μl) were 
added to the mixture and incubated at 37° C for 2 minutes. 1μl of M-MLV 
RT (200U) was added to each mix and the samples were incubated at 37° 
C for 50 minutes. The reaction was inactivated at 70° C for 15 minutes. 
cDNA was quantified using spectrophotometric technology (Biorad, USA) 
and analyzed by TaqMan qPCR. 
 
D4: RNA Extraction from Rat Tissues 
TRIzol (Thermo fisher scientific, USA) is a chemical solution used for the 
extraction of RNA, DNA and proteins. Briefly 25 mg of tissue was 
homogenized using specific bead combinations and the bullet blender 
homogenizer (Next Advance, USA) in 500 μl of Trizol. The lysate was 
centrifuged at max speed for 1 minute and 250 μl of reaction was mixed 
with 750 μl of Trizol and incubated at RT for 5 minutes. 200 μl of 
chloroform was added to the mixture and incubated at RT for three 
minutes. The mix was centrifuged at 12,000xg for 15 seconds at 4˚C to 
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allow the separation into different phases, the lower red phenolo-
chloroform phase, an interphase and a colorless upper aqueous phase 
containing the RNA. The top phase was collected and mixed with 500 μl of 
100% isopropanol at RT for 10 minutes. Samples were centrifuged at 
12,000xg for 10’ at 4˚C. The pellet was washed with 1ml of 75% ethanol 
and centrifuged at 7500 g for 5 minutes at 4˚C. RNA was resuspended in 
40 μl of RNase free water and stored at -70 C. 
 
D5: PCR on TZM-bl Cells 
300 ng of DNA purified from TZM-b1 cells transduced with lenti SpCas9 
LTR -80/ +66 and gRNAs A and B in presence of different concentrations 
of Tat was subjected to LTR PCR amplification (94 °C 5 min, 30 cycles 
(94˚C 15 s, 55˚C 30 s, 72˚C 30 sec) and 72˚C 5min) using Fail Safe kit, 
buffer D (Epicentre, USA) and 0.2 μM of the primers listed in table 6. The 
same PCR was performed on TZM-b1 lenti LTR-80/+66 Cas9 stable line 
transduced with different amounts of gRNAs and infected with HIV-1JRFL 
and HIV-1SF162. 
 
D6: qPCR on Jurkat 2D10 cells 
RNA purified from Jurkat 2D10 cells was assessed by qPCR using 
Platinum Taq DNA polymerase (Invitrogen, USA). Each sample was 
analyzed in triplicate, such as the standards.  
The reaction was prepared as follows: 
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COMPONENT VOLUME/REACTION 
PlatinumTM Taq DNA polymerase* 0,1 μl 
Buffer 10X 2 μl 
dNTPs mix (25 uM) 0,16 μl 
50 mM MgCl2 1.2 μl 
forward Primer (100 μM) 0,1μl 
reverse Primer (100 μM) 0,1 μl 
probe 100 μM) 0,1 μl 
DNA sample 50 ng 
Deionized Water To 20 μl 
*Thermo Fisher Scientific (#10966034) 
 
Table 15: qPCR Conditions to detect viral DNA in Jurkat 2D10 cells. Reactions were 
performed in 50 μl using two LTR FAM coniugated probe to detect the ratio between 
truncated versus full length LTR as index of efficiency of viral excision. 
 
D7: PCR on Jurkat 2D10 cells 
PCR was performed on a conventional PCR machine (T100 Thermal 
Cycler, Biorad, CA, USA) in 25 μl of buffer D, 1μl of Fail Safe enzyme and 
300 ng of DNA sample. PCR specific for LTR region was performed in 
Jurkat 2D10 -80/+66 Cas9 cell line transduced with different amounts of 
gRNAs in presence or absence of Tat. PCR product was resolved on 2% 
agarose gel detecting one 427 base pairs wild type LTR fragment and one 
227 base pairs truncated LTR fragment. Specific PCRs for 5’UTR, env and 
B-actin were performed on DNA purified from Jurkat cells transduced with 
Cas9 and gRNAs A/B and HIV-1 infected using primers listed in table 6. 
The sizes of the amplicons were 139, 150 and 270 base pairs respectively. 
LTR PCR revealed one 395 base pairs wild type fragment and one 205 
base pairs truncated LTR. PCR conditions were as follows: 94 °C 5 min, 30 
cycles (94 °C 15 s, 55 °C 30 s, 72 °C 30 sec and 72C 5 min. 
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APPENDIX E:  TG26 Mice and Rat Model 
Tg26 mice were crossed into the C57BL/6L background to generate 
animals able to survive to 12 months of age and where clinical 
manifestation, associated to a low level of expression of viral transcripts, is 
largely reduced. Tg26 mice and rats were used for studies in vivo to test 
the ability of the construct AAV9 saCas9 LTR1/GagD. Both animal models 
encompasse a sequence of HIV-1 NL4-3 with a deletion of a 3.1 kb from the 
C-terminal of the Gag gene to the N-terminal of the Pol gene (Figure 53). 
This delivery system is associated with the use of saCas9, derived from 
Staphylococcus aureus, 1 kb shorter than spCas9 allowing the use of one 
vector for the delivery of Cas9 and gRNAs together. 
 
 
 
Figure 53: Schematic representation of the Tg26 mouse containing HIV-1 DNA. The 
mice harbour HIV-1 genome with a missing portion between gag and pol region. The region 
covered by the primers used for to detect viral excision are illustrated on the top of the 
figure. The position of the LTR1 and GagD gRNAs is shown by arrows. (Figure reproduced 
with permission from Kaminski R. et al., 2016 and Nature Publishing group) [186]. 
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APPENDIX F: Humanized Mice Model and AAV9/CRISPR/Cas9 
Treatment  
Nod/Cg-Prkdcscid II2rgtm1wjI/SzJ (NSG) mice were used for study the ability 
of AAV9SaCas9LTR1GagD to induce gene editing in humanized animal 
model. The experiments on humanized mice were performed by 
collaborators from the University of Nebraska Medical Center. Briefly 104 
human peripheral blood lymphocytes (PBLs) were injected by intrahepatic 
injection for each newborn mouse, previously irradiated with C9cobalt60.  
18 weeks old mice were infected with HIV-1NL4-3 (105 tissue culture infective 
dose 50/ml); of the following mice, 5 received no antiretroviral treatment 
and one injection of AAV9 construct, and 13 were treated with a long acting 
slow effective release ART therapy (LASER ART) using 40-45 mg of a 
cocktail of antiretroviral drugs such as rilpivirine, myristolyated dolutegravir, 
lamivudine and abacavir. After 6 weeks of ART therapy the animals under 
retroviral drugs were successively divided in non Cas9 treatment (4 mice) 
and Cas9 treated (9 mice). Five control mock animals were used as 
negative control. Tissues were harvested after 5 weeks from CRISPR 
treatment in absence of antiretroviral treatment.  
 
Figure 54: Schematic representation of mouse humanization, viral infection, ART 
initiation and CRISPR/Cas9 treatment. Infection was perfomed at week 0, a combination 
of antiretroviral drugs was somministarted for 4 weeks, three weeks later one single 
injection of AAV9-CRISPR-Cas9 was injected and tissues were harvested at week 14. 
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